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Summary 
The aim of this thesis was to functionally characterize the role of the transcription factor SOX6 in Ewing 
Sarcoma (EwS), since preliminary findings revealed that SOX6 is highly expressed in EwS patients. 
EwS is a bone or soft tissue tumor characterized by a fusion oncogene called EWSR1-FLI that has been 
shown to regulate its target genes through GGAA-microsatellites (mSat). So far, it has been demonstrated 
that SOX6 is actively expressed and it is essential for bone development during the endochondral 
ossification step, suggesting the importance of further analysis of this gene in a bone tumor such as EwS. 
In fact, the presented data in this thesis revealed a new insight into the regulation of the transcription 
factor SOX6 and its therapeutic vulnerability toward the oxidative stress-inducing drug Elesclomol. 
Preliminary experiments showed, that the transcription factor SOX6 is highly expressed in EwS patients, 
whereas its overexpression did not correlate with patient’s survival.  
For functional experiments, EwS cell lines were generated to induce SOX6 knockdown via a doxycycline 
(Dox)-inducible shRNA against SOX6. Reporter assays demonstrated that EWSR1-FLI1 hijacks SOX6 via its 
binding to an intronic GGAA-mSat. Transcriptome-profiling and Gene Set Enrichment analysis (GSEA) 
offered valuable clues about the role of SOX6 in EwS resulting in proliferation-related signatures, which 
were confirmed by functional assays. SOX6 appears to be involved in cell cycle progression in vitro and 
in the promotion of tumor growth in vivo. Further analyses in combination with drug-screening data 
pointed out a strong sensitivity of EwS cells toward the oxidative stress-inducing small molecule 
Elesclomol. This drug is known to be an oxidative-stress inducing agent that exerts its potency by binding 
copper and transporting it into the mitochondria. There it produces free radicals inside the cell leading 
to mitochondrial apoptosis. In addition, transcriptome-profiling analysis revealed that the second most 
downregulated gene, upon SOX6 knockdown, is thioredoxin-inhibitor protein (TXNIP), which may 
partially explain the observed sensitivity toward Elesclomol. As part of the antioxidant system TXNIP 
regulates the oxidative stress levels within the cell by inhibiting thioredoxin. In agreement to this, the 
data reported in this thesis demonstrated that constitutively high SOX6 expression promotes elevated 
levels of oxidative stress that create a therapeutic vulnerability toward Elesclomol in EwS.  
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1. Introduction 
1.1 Ewing Sarcoma 
1.1.1 Origin 
Ewing sarcoma was first described as a “diffuse endothelioma of the bone” by James Ewing in 1921 
(Ewing, 1921) and only later became known as Ewing sarcoma (EwS).  
Ewing sarcoma family of tumors are grouped together based on morphological and 
immunohistological features as well as the presence of a common chromosomal translocation (mainly 
EWSR1-FLI1). They include the classical osseous Ewing sarcoma, extraosseus Ewing sarcoma, Askin 
tumor and peripheral primitive neuroectodermal tumors (PNET) (Kovar, 1998). 
Although the origin of this tumor is still debated, there is evidence of being potentially originated from 
a mesenchymal stem cell with an osteo-chondrogenic progenitor (Tanaka et al., 2014; Tirode et al., 
2007). Tirode and colleagues showed that upon EWSR1-FLI1 silencing, EwS cell lines cultured in the 
appropriate differentiation medium, were able to differentiate into different lineages showing a more 
mesenchymal stem cell expression profile (Tirode et al., 2007). Additionally, Riggi and colleagues 
showed that ectopical expression of EWSR1-FLI1 in human mesenchymal stem cells resembles EwS 
cells (Riggi et al., 2008) and the ectopic expression of EWSR1-FLI1 on murine primary bone-derived 
stem cells induces Ewing sarcoma-like tumors in vivo (Castillero-Trejo et al., 2005; Riggi et al., 2005). 
 
1.1.2 Molecular and genetic profile of EwS 
Generally, EwS is characterized by a somatic chromosomal in frame translocation of the 5’–EWS gene 
(EWSR1, Ewing sarcoma breakpoint region 1) with one of the 3’–ETS family of transcription factor 
members (FLI1, ERG, ETV1, ETV4, FEV, PATZ1, SP3, NFATC2, SMARCA5, E1AF, ZSG). The resulting 
translocations are present in sarcomas, exclusively (Riggi and Stamenkovic, 2007). In 85% of EwS cases 
the EWSR1 gene on p22q12 is fused with the FLI1 gene on p11q24 resulting in a chimeric fusion 
transcript EWSR1-FLI1 (Anderson et al., 2018; Delattre et al., 1992). 
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The characteristic EWSR1 gene on chromosome 22 belongs to the TET protein family and contains a 
protein-RNA binding domain (Bertolotti et al., 1996). On the other hand, the ETS transcription factors 
bind to promoters resulting in transcriptional activation or repression of their target genes. They 
preferentially bind to a DNA core motifs of 5’-GGAA/T-3’ (Dittmer, 2011). The Friend leukemia 
integration 1 gene (FLI1) is a member of the ETS factors and is mostly expressed in hematopoietic cells 
in adult tissue (Ben-David et al., 1991). This fusion oncogene is known not only to bind GGAA-core 
motifs but also consecutive GGAA-repeats so-called GGAA-microsatellites (mSats), whose enhancer 
activity increases with the number of consecutive GGAA-motifs (Boulay et al., 2017; Gangwal and 
Lessnick, 2008; Gangwal et al., 2008; Guillon et al., 2009; Riggi et al., 2014). Thus, EWSR1-FLI1 partly 
regulates some of its target genes (ERG, MYBL2 and NR0B1) and mediates EwS tumorigenesis 
(Grünewald et al., 2015; Kinsey et al., 2006; Musa et al., 2019). 
The chromosomal translocation between EWSR1 and FLI1 mostly occurs in two modalities: Exon 7 of 
EWSR1 fuses to exon 6 of FLI1 (type 1) or exon 7 of EWSR1 fuses to exon 5 of FLI1 (type 2), the latter 
accounting for 85% of cases (Delattre et al., 1992, 1994; Turc-Carel et al., 1988). In contrast to earlier 
assumptions, both fusion types have the same prognostic outcome (Le Deley et al., 2010). In 10–15% 
of EwS cases gene on p22q12 is fused to p21q12 resulting in the EWSR1-ERG chimeric gene (Sorensen 
et al., 1994). The generated fusion protein is an aberrantly expressed oncogenic transcription factor. 
 
1.1.3 Clinical aspects: epidemiology, diagnosis and therapy 
After osteosarcoma, EwS represents the second most common bone and soft-tissue tumor (Grünewald 
et al., 2018) in children, adolescents and young adults (Esiashvili et al., 2008), accounting for 3% of all 
pediatric cancers (Resnick and Kransdorf, 2005). The incidence of this rare disease is ~1.5 cases per 
1.000.000 each year and is more common in Caucasian than African or Asian populations (Beck et al., 
2012; Esiashvili et al., 2008; Khoury, 2005; Paulussen et al., 2009). The average peak age is 10–24 years 
and males are slightly more affected than females at a ratio of about 3:2 (Paulussen et al., 2008a). 
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Although EwS can virtually arise from every part of the body, the most common sites are Pelvis (25%), 
Femur (16%), Ribs (12%) and Tibia (8%). Interestingly, it can also develop in soft tissues without direct 
affection of the bone (Cotterill et al., 2000; Resnick and Kransdorf, 2005).  
Molecular analysis of EwS can be done by immunohistochemistry (IHC). This trend-setting method is 
based on the detection of CD99, a surface antigen that is expressed in 90% of EwS cases (Khoury, 2005). 
Diagnosis based on the conventional immunohistochemical marker CD99 is however unspecific as it 
can be detected in other small round cell tumors such as lymphoblastic lymphoma, 
rhabdomyosarcoma, synovial sarcoma, mesenchymal chondrosarcoma, blastemal component of 
Wilms tumor, and rarely in desmoplastic small round cell tumors (DSRCT) (Folpe et al., 2000). In the 
backlight of this, Baldauf and colleagues recently suggested three potential biomarkers (BCL11B, GLG1 
and ATP1A1) that could help to reduce misdiagnosis due to the aforementioned poor specificity of 
CD99 (Baldauf et al., 2018a). Currently, the final diagnosis of EwS is made by detecting the fusion 
oncogene EWSR1-ETS using PCR or FISH methods. 
Especially in the case of metastatic or recurrent disease, the effectiveness of EwS patient treatment 
remains dismal (Gaspar et al., 2015). The survival and treatment options heavily depend on the fact of 
whether patients already present metastasis at diagnosis or not. The 5-year survival rate of patients 
with localized tumors is approximately 70−80% after diagnosis (Grier et al., 2003; Le Deley et al., 2010; 
Paulussen et al., 2008b; Womer et al., 2012). The current treatment for localized tumors is surgery 
and/or radiotherapy (Cotterill et al., 2000; Gaspar et al., 2015; Grünewald et al., 2018).  
In 20–25% of the cases, EwS patients have metastasis at diagnosis in bone, bone marrow or lungs and 
are unfortunately resistant to established treatment regimes. Their 5-year survival rate drops 
dramatically compared to localized tumors onto < 30%, whereas patients with restricted lung 
metastasis have a survival rate of ~ 50% (Cotterill et al., 2000; Gaspar et al., 2015).  
Treatment options include high dose of polychemotherapy (Doxorubicin, Etoposide, Ifosfamide and 
Vincristin) in combination with radiotherapy and surgical resection (Gaspar et al., 2015).  
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However, the efficacy of these treatments is limited for patients with metastatic or recurrent tumors 
(Gaspar et al., 2015). In fact, approximately 30–40% of the EwS patients suffer from recurrent tumors 
and their survival rate is devastating with less than 20–25% (Ahrens et al., 1999). There is no specific 
treatment protocol for recurrent tumors, but current practices include resection, chemotherapy and 
radiotherapy. This highlights the urgency of novel therapeutic options that are needed to improve the 
outcomes of these patients. 
 
1.2 SRY-related HMG-box 6 (SOX6) 
1.2.1 SOX family of transcription factors  
The SOX (SRY-related HMG-box) family genes encode an important group of transcription factors (TF). 
They harbor a conserved high mobility group (HMG) DNA binding domain that was originally identified 
in the mouse and human testis-determining gene Sry residing on the Y-chromosome (Berta et al., 1990; 
Cohen-Barak et al., 2001; Gubbay et al., 1990).  
The HMG-box is a 79 amino-acid DNA binding domain (DBD) that is highly conserved (Stros et al., 2007) 
among SOX gene family members of vertebrate and invertebrates. All proteins that share at least 50% 
similarity to the HMG box of Sry are referred to as SOX proteins. All SOX family genes have a crucial 
role in cell fate decision during development (Sarkar and Hochedlinger, 2013). 
Based on sequence homology, SOX genes can be further categorized into six subfamilies (Cohen-Barak 
et al., 2001; Pevny and Lovell-Badge, 1997) one of these is the SOXD subfamily, which comprises the 
transcription factors SOX5, SOX6 and SOX13. Interestingly, SOXD subfamily proteins do not possess a 
known trans-activation or trans-repression domain (Han and Lefebvre, 2008; Lefebvre et al., 1998). 
Additionally, SOXD proteins possess uniquely two highly conserved leucine-zipper coiled-coil domains 
that allows homo-dimerization resulting in high-efficiency binding on DNA (Lefebvre et al., 2007).  
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1.2.2 SOX6 gene: Structure and regulation 
In this thesis, the focus will be set mainly on the transcription factor SOX6. The transcription factor 
SRY-box 6 (SOX6) was discovered to be located on the 16 exon-containing human chromosome 
11p15.3-p15.2 (Cohen-Barak et al., 2001). SOX6 is a 92 kDa protein that was initially isolated from an 
adult mouse testis cDNA library and comprises three isoforms (Denny et al., 1992). 
As part of the SOXD subfamily, SOX6 is forced to homo-or heterodimerize with other proteins and 
various cofactors (Hagiwara, 2011) in order to activate or repress gene expression (Kamachi et al., 
2000; Lefebvre et al., 1998). The SOXE subfamily, including Sox8/9/10, contain an activator domain 
and represent an important interacting partner of SOX6 (Kamachi et al., 2000; Wegner, 1999). 
The SOXD family member SOX5, a cofactor of SOX6, shares sequence similarity (Hagiwara, 2011; 
Koopman et al., 2004). Both act together with redundant functions in chondrogenesis and 
oligodendrocyte development (Hagiwara, 2011; Smits et al., 2001; Stolt et al., 2006). Moreover, it has 
been demonstrated in mice that Sox5/6 complex interact together with Sox9, which possess an 
activator domain, to promote cartilage specific genes (Akiyama et al., 2002; Hagiwara, 2011; Han and 
Lefebvre, 2008; Kamachi et al., 2000; Lefebvre et al., 1998; Stolt et al., 2006). Contrarily, Sox5/Sox6 
antagonize Sox9 as an activator during oligodendrocyte development (Stolt et al., 2006).  
 
 
Among the SOX family of transcription factors, especially SOX6 is considered functionally very versatile 
due to its unique structure:  
1) SOX6 does not contain any known regulatory domain; instead it utilizes various cofactors (listed in 
(Hagiwara, 2011)). 2) SOX6 possesses a long 3’–UTR region (Bartel, 2009) containing multiple micro 
RNA (miRNA) target sequences  that enable the tissue-specific microRNAs to control SOX6 expression 
in certain tissues (Table 1):  
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miRNA Function Reference 
miR-16 
Suppresses cell apoptosis while promoting cell 
proliferation in esophageal squamous cell carcinoma. 
(Zhu et al., 2014) 
miR-18a Targets SOX6 in cervical cancer. (Dong et al., 2018) 
miR-19b 
Promotes cell proliferation during cardiac differentiation 
by targeting Sox6 expression. 
(Han et al., 2018) 
miR-96 
Targets SOX6 and promotes proliferation, migration and 
invasion of hepatocellular carcinoma. 
(Li and Wang, 2017) 
miR-103 
Inhibits chondrocyte proliferation in osteoarthritis 
development. 
(Chen and Wu, 2019) 
miR-122 
Targets SOX6 and promotes carcinogenesis of glioma 
cells. 
(Chen et al., 2019) 
miR-129-5p 
Alleviates nerve injury and inflammatory response of 
Alzheimer’s disease via SOX6 downregulation. 
(Zeng et al., 2019) 
miR-132-3p 
Inhibits osteogenic differentiation of ligamentum flavum 
cells by targeting SOX6. 
(Qu et al., 2016) 
miR-135a-5p Regulates Sox6 expression in neuronal differentiation. (Li et al., 2019) 
miR-155 
Aberrant expression of microRNA-155 may accelerate 
cell proliferation by targeting sex-determining region Y 
box 6 in hepatocellular carcinoma. 
(Xie et al., 2012) 
miR-181b 
Targets SOX6 to decrease proliferation and metastasis in 
lung cancer cells. 
(Zhou et al., 2019) 
miR-202 Promotes endometriosis by regulating SOX6 expression. (Zhang et al., 2015) 
miR-208 
Represses SOX6 expression in human esophageal 
squamous cell carcinoma. 
(Li et al., 2014) 
miR-208a,b Involved in cardiac hypertrophy by targeting Sox6 (Soci et al., 2016) 
miR-219 
Required for normal oligodendrocyte differentiation and 
myelination. 
(Dugas et al., 2010; 
Zhao et al., 2010) 
miR-499 
Regulates cell proliferation and apoptosis during late-
stage cardiac differentiation via Sox6 and cyclin D1. 
(Li et al., 2013) 
miR-499-5p 
Regulates porcine myofiber specification by controlling 
Sox6 expression. 
(Wang et al., 2017) 
miR-508-3p Targets SOX6 in melanogenesis. (Liu et al., 2018) 
miR-671 
Promotes prostate cancer cell proliferation by inhibiting 
SOX6. 
(Yu et al., 2018) 
miR-765 
Regulates proliferation and apoptosis in multiple 
myeloma. 
(Long et al., 2019) 
miR-766 
Regulation of cell proliferation in human colorectal 
cancer. 
(Li et al., 2015) 
miR-1269a 
Regulation of SOX6 expression in non-small cell lung 
cancer  
(Jin et al., 2018) 
Table 1: Overview of microRNAs (miRNA) that regulate SOX6 expression in different tissues or tumor 
entities. 
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Besides its role as a DNA-binding transcription factor, SOX6 also emerges as an RNA-binding and 
bending factor that controls pre-mRNA splicing and mRNA translation (Ohe et al., 2009). All these facts 
underline the role of SOX6 as a multifaceted protein. 
 
 
 
1.2.3 SOX6 function in vertebrate development 
Previous studies have suggested that Sox6 plays a role in the development of the central nervous 
system (CNS) (Dugas et al., 2010; Stolt et al., 2006; Zhao et al., 2010) and chondrogenesis in mice 
embryos (Akiyama et al., 2002; Lefebvre and Smits, 2005; Lefebvre et al., 1998; Smits et al., 2001, 
2004). However, most of the SOX genes, especially Sox6, are differentially expressed in multiple 
development stages of different tissues with different effects at each step (Akiyama et al., 2002; 
Hagiwara, 2011; Lefebvre and Smits, 2005) (Table 2). 
In mice, Sox6 is expressed in the central nervous system (CNS) during embryogenesis, but later on 
decreases in the adult CNS (Azim et al., 2009). In humans, SOX6 is expressed in the brain during 
embryogenesis and remains at only very low levels in the adult brain (Ueda et al., 2004a, 2004b).  
 
What? Function Reference 
Differentiation of mesenchymal tissues 
Chondro- 
cyte 
Sox5/Sox6 regulates proliferative 
chondroblasts during cartilage 
differentiation. 
(Akiyama et al., 2002; Lefebvre and 
Smits, 2005; Lefebvre et al., 1998; 
Smits et al., 2001, 2004) 
Skeletal 
muscle 
Sox6 is involved in specification of muscle 
fiber types. 
(Hagiwara et al., 2007; von Hofsten 
et al., 2008) 
Development of central nervous system (CNS) 
Oligodendro-
cyte 
Sox5/Sox6 regulates proliferative 
oligodendrocyte progenitor cells 
differentiation. 
(Dugas et al., 2010; Stolt et al., 
2006; Zhao et al., 2010) 
Neurons Sox6 specifies post-mitotic interneurons. (Azim et al., 2009) 
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Differentiation of other cell and tissues 
Erythropoiesis 
Sox6 regulates proliferation and 
maturation of red blood cells. 
(Cohen-Barak et al., 2007; Dumitriu, 
2006; Dumitriu et al., 2010; Xu et al., 
2010; Yi et al., 2006) 
Pancreatic 
β-cells 
Sox6 regulates glucose-stimulated insulin 
secretion from β-cells. 
(Iguchi et al., 2005, 2007) 
Cardiomyo-
cyte 
Sox6 regulates proliferative cardiomyocyte 
progenitor cells. 
(Sluijter et al., 2010) 
Testis 
Sox6 regulates proliferation in 
spermatogenesis.  
(Hagiwara, 2011; Yamashita et al., 
2000) 
Table 2: Sox6 function in mesenchymal differentiation, development of the CNS or in differentiation 
of different tissues. 
 
In mice, Sox6 appears to be mainly involved in the proliferation process of cardiomyo-, chondro and 
oligodendrocytes progenitor cells, but not in post-mitotic differentiating cells. Controversially, Sox6 
may be involved in differentiation of post-mitotic interneurons (Azim et al., 2009; Batista-Brito et al., 
2009) and specification of muscle fiber types (Hagiwara et al., 2007).  
Depending on the cellular context, SOX6 has two major functions: 1) to control the cell cycle exit during 
terminal differentiation and 2) to regulate terminal differentiation of post-mitotic cells (Hagiwara, 
2011).  
 
 
1.2.4 Role of SOX6 in endochondral ossification 
Among the several functions of SOX6, the major interest of this thesis is its role in endochondral 
ossification, because dysfunction of this process might promote development and progression of a 
bone-related tumor such as EwS. 
Endochondral ossification (Figure 1) is driving formation and growth of long bones (vertebrae, ribs and 
limbs) as well as promoting the healing of bone fractures. This ossification pathway is characterized by 
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mesenchymal stem cell (MSC) progenitors going through a cartilage intermediate and finally 
transforming into new bone tissue (Horton et al., 1988; Quintana et al., 2009).  
 
Figure 1: Main steps in endochondral ossification (1 – 5) and key transcription factors. 
 
Chondrogenesis is a crucial step in endochondral ossification and starts with the condensation and 
growth arrest of mesenchymal progenitors to the osteo-/chondrogenic progenitor cells (Figure 1(2)), 
through migration to the sites where bone will develop. For this step, proliferation associtated genes 
are downregulated, wheras differentiation-associated genes are expressed to induce chondrogenic 
differentiation (Figure 1(1)). The whole bone development is controlled by many signaling molecules 
such as TGF-β, BMPs or the Indian hedgehog (Ihh) pathway.  
The chondrogenic differentiation pathway is regulated by the transcription factor SOX9 that allows the 
proliferation and differentiation of MSC into chondroblasts (Akiyama et al., 2002; Bi et al., 1999). Those 
progenitors keep expressing SOX9 to form a dense structure mass by producing collagens. 
The additional time-restricted co-expression of the SOX5/SOX6 genes (then referred to as SOX-trio) 
(Figure 1(3)) enable chondroblasts to proliferate (Figure 1(4)) to start synthesizing/ secreting 
extracellular matrix (ECM) components to form a scaffold for osteoblasts (Hagiwara, 2011; Lefebvre et 
al., 1998; Quintana et al., 2009).  
At a certain timepoint, when the SOX-trio level decreases (Figure 1(5)), and other factors important 
for differentiation such as RUNX2 or OSX are upregulated, chondroblasts undergo chondrocyte 
maturation (Lefebvre et al., 1998; Quintana et al., 2009). The regulation of proliferating chondroblasts 
is under control of SOX6, which inhibits the precocious exit from the cell cycle, thereby preventing 
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chondroblasts from entering pre-hypertrophic stage too early (Hagiwara, 2011; Lefebvre et al., 1998; 
Smits et al., 2004). 
Chondrocytes exit the cell cycle, become hypertrophic and initiate the endochondral ossification 
process mainly by degrading the ECM. This step includes among others the mineralization of the 
cartilage matrix with calcium salts (Quintana et al., 2009). Subsequently, hypertrophic chondrocytes 
undergo apoptosis to form a cartilaginous scaffold for blood vessels carrying osteoblastic progenitors 
(Quintana et al., 2009) (Figure 1(5)).  
So far, it has been reported that Sox6 single-knockout mice die prematurely and showed mild skeletal 
abnormalities compared to mice with Sox5/Sox6 double-knockout, that revealed severe 
chondrodysplasia (Smits et al., 2001). Thus, although Sox5 and Sox6 have redundant functions both 
are essential for endochondral ossification (Smits et al., 2001). 
 
1.2.5 SOX6 expression in tumors and other malignancies 
The transcription factor SOX6 is mostly expressed during the development of the CNS and in the early 
stages of chondrogenesis. In adult tissues, SOX6 is thought to maintain functionality of specific tissues 
but its role in adults is still unclear (Hagiwara, 2011). The enormous versatility of SOX6 is also mirrored 
by its role in tumorigenesis, where it can act either as an oncogene or as a tumor suppressor gene, 
depending on the cellular context. 
On the one hand, it has been reported that the expression of SOX6 acts as a tumor suppressor in 
esophageal squamous cell carcinoma (Qin et al., 2011) and hepatocellular carcinoma (Guo et al., 2013). 
On the other hand, SOX6 was found to be overexpressed in melanoma cells compared to neural-crest 
deriving melanocytes probably supporting an oncogenic role (Le Douarin and Kalcheim, 1999).  
Additionally, Ueda and colleagues, discovered that SOX6 is overexpressed in glioma tissues including 
glioblastoma, oligodendroglioma and astrocytoma (Ueda et al., 2004a). Interestingly, over-expression 
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of SOX6 was not found in more differentiated brain tumors indicating that the effect of SOX6 become 
apparent in multipotent cells that are still prone to differentiation.  
In addition to that, as previously mentioned, the transcription factor SOX6 is known to be involved in 
cell cycle progression during cartilage differentiation. This observation and the fact that EwS is 
characterized as an immature and highly proliferative bone-associated tumor makes SOX6 an 
interesting variable to analyze in the context of EwS progression.  
 
1.3 Oxidative stress and the role of TXNIP 
Tumors are typically characterized by higher oxidative stress levels than non-malignant cells through 
increased metabolic activity. This observation holds true for EwS, generally displaying heightened 
oxidative stress levels compared to normal tissues (Benz and Yau, 2008; Grünewald et al., 2012).  
On the one hand elevated oxidative stress levels are important to maintain tumor properties but on 
the other hand an extensive oxidative stress production make them susceptible to specific drugs that 
are able to induce oxidative stress (Trachootham et al., 2009). Therapeutically, utilizing the properties 
of the oxidative stress mechanism within tumor cells appears to be a promising option. Successful trials 
have already been able to exploit this mechanism by increasing the levels of oxidative sress over a 
tolerable dose in form of a anticancer therapy (Gibellini et al., 2010).  
The electron respiratory chain in mitochondria is the predominant source of aerobic energy production 
in mammalian cells and also the main location of oxidative stress production. Normal cells maintain a 
redox homeostasis as balanced levels of oxidative stress are important for certain cellular processes 
such as gene expression, cell proliferation and signal transduction (Mikkelsen and Wardman, 2003). 
Hence, a functional antioxidant machinery is crucial to maintain this homeostasis as increased 
oxidative stress levels interact with lipids, proteins, nucleic acids and cell death programs, thereby 
damaging the cells.  
One of these antioxidant machineries is the thioredoxin system. The thioredoxin system is composed 
of thioredoxin (Trx), thioredoxin reductase (TrxR), the coenzyme α-nicotinamide adenine dinucleotide 
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phosphate (NADPH) and the thioredoxin-interacting protein (TXNIP). Two thioredoxin antioxidant 
machineries are present within the cell; Trx1 is located in the cytoplasm whereas Trx2 is only located 
in the mitochondria. 
TXNIP was originally identified as Vitamin D3 upregulated protein 1 (VUP1) (Chen and DeLuca, 1994) 
and is known to be mainly involved in the redox system and apoptosis, but it has become clear that 
the role of TXNIP extends beyond the Trx antioxidant system. In fact, in the last few years this protein 
has emerged as a regulator of lipid and glucose metabolism and become linked to diabetes mellitus. 
Mainly, TXNIP is involved in the redox antioxidant system where it inhibits Trx, consequently leading 
to an oxidative stress accumulation within the cell. The ability of TXNIP to induce oxidative 
stress-mediated apoptosis and the fact that TXNIP is often reduced in tumor tissues such as 
hepatocellular, breast and bladder carcinoma (Zhou and Chng, 2013), suggest that TXNIP is indeed a 
tumor suppressor. 
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2 Research objectives and scientific aims 
2.2 Research objectives 
EwS seems to arise from osteo-/chondrogenic progenitor cells and those are characterized as highly 
proliferative and undifferentiated cells. Therefore, the underlying hypothesis was that SOX6, being 
highly overexpressed in EwS, is critical for EWSR1-FLI1 mediated arrest of EwS cells in an early-
committed differentiation state and that SOX6 is part of the EWSR1-FLI1-induced transformation 
program.  
This PhD project aimed at functionally characterizing the mechanism by which EWSR1-FLI1 drives SOX6 
expression and at unveiling the role of SOX6 in tumorigenesis and progression of EwS in vitro and in 
vivo. Moreover, it was hypothesized that SOX6 might serve as a valuable biomarker for EwS treatment. 
 
2.3 Scientific aims 
1st aim:  Assessment of the enhancer activity and EWSR1-FLI1 occupancy of the SOX6 GGAA-
microsatellite. 
2nd aim:  Analysis of the effect of SOX6 on the phenotype of EwS in vitro. 
3rd aim: Analysis of the SOX6 effect on the differentiation capacity of EwS cells. 
4th aim: Evaluation of the impact of SOX6 on the phenotype of EwS in a xenograft model. 
5th aim: Identification and validation of indirect and direct SOX6 target genes. 
6th aim: Exploration of a therapeutic vulnerability due to SOX6 in EwS. 
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3. Materials and methods 
3.1 Materials 
3.1.1 List of manufacturers 
 
Manufacturer Location 
(Carl) Roth  Karlsruhe, Germany 
Abcam Cambridge, UK 
Agilent Technologies Santa Clara, USA 
Alpha Innotech Kasendorf, Germany 
Applied Biosystems  Darmstadt, Germany 
ATCC  Rockyville, Maryland, USA 
Atlas Antibodies Bromma, Sweden 
B. Braun Melsungen AG Melsungen, Germany 
BD Biosciences Europe  Heidelberg, Germany 
Beckman Coulter  Palo Alto, California, USA 
Bela-Pharm Vechta, Germany 
Berthold detection systems  Pforzheim, Germany 
Biochrom  Berlin, Germany 
BioRad  Richmond, California, USA 
BIOTECH (siTOOLs) Munich, Germany 
Biozym  Hess. Olendorf, Germany 
Beurer GmbH Ulm, Germany 
Brand Wertheim, Germany 
Braun Biotech international GmbH Melsungen, Germany  
Cell Marque Corporation Rocklin, California, USA 
Cell Signaling Technology Frankfurt a. M., Germany 
Corning incorporated New York, USA 
Dechra Veterinary Products Aulendorf, Germany 
Eppendorf Hamburg, Germany 
Falcon  Oxnard, California, USA 
Fischer Scientific Schwerte, Germany 
Fryka Esslingen am Neckar, Germany 
GE Healthcare  Freiburg, Germany 
Gilson Incorporated Middleton, USA 
Greiner  Nürtingen, Germany 
Hamilton Company Nevada, USA 
Hartenstein Würzburg, Germany 
Heidolph Instruments Schwabach, Germany 
Heraeus  Hanau, Germany 
HP Labortechnik München, Germany 
INTEGRA biosciences Zizers, Switzerland 
Invitrogen  Karlsruhe, Germany 
InVivoGen San Diego, California, USA 
Julabo  Seelbach, Germany 
Leica Biosystems Wetzlar, Germany 
LI-COR Nebraska, USA 
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Life Technologies California, USA 
Macherey-Nagel  Düren, Germany 
Merck Millipore Burlington, Massachusetts, USA 
Mergo GmbH & Ko KG Wesel, Germany 
New England BioLabs Frankfurt a. M., Germany 
Nordcap Bremen, Germany 
Nunc  Naperville, USA 
OriGene Technologies Rockville, Maryland, USA 
Pechiney Plastic Packaging Menasha, Wisconsin, USA 
Prodivet pharmaceuticals Raeren, Belgium 
PJK GmBh Kleinblittersdorf, Germany 
Promega  Madison, Wisconsin, USA 
Qiagen Chatsworth, California, USA 
OriGene Technologies Rockville, USA 
Quartett Biochemicals Berlin, Germany 
Richter Pharma AG Wels, Austria 
Roche  Mannheim, Germany 
Santa Cruz Biotechnology Heidelberg, Germany 
Sartorius Göttingen, Germany 
Scientific industries New York, USA 
Selleckchem Munich, Germany 
Sigma  St. Louis, Missouri, USA 
System Biosciences Palo Alto,California, USA 
Taconic Denmark ApS Silkeborg, Denmark 
The Jackson Laboratory Bar Harbor, USA 
Takara Bio Europe  Saint-Germain-en-Laye, France 
Thermo Fisher Scientific  Ulm, Germany 
Thermo Scientific  Braunschweig, Germany 
Vector Laboratories California, USA 
Whatman  Dassel, Germany 
WTW Weilheim, Germany 
Zeiss Oberkochen, Germany 
 
3.1.2 General materials 
 
Material Manufacturer 
6, 12, 24 and 96-well-plate Corning Incorporated 
96-well-plate (white) Corning Incorporated 
Amersham Protran 0.45 nitrocellulose Western 
blotting membranes 
GE Healthcare 
Blotting paper Hartenstein 
Cell culture flasks (150, 75, 25 cm2) Corning Incorporated 
Cell scraper Corning Incorporated 
Costar Ultralow attachment plates 96-well Corning Incorporated 
CryoGen Hartenstein 
Eppendorf Tubes (1.5 and 2 ml) Hartenstein 
Falcon Tubes (15 ml and 50 ml PP or PS) Falcon  
HandyStep electronic Brand 
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Heating lamp Beurer GmbH 
Needle for orthotopic injection (Small Hub RN 
Needle (28/20/4) and syringe) 
Hamilton Company 
Nunclon cell culture dish (10 cm2) Thermofisher 
Optical adhesive film for 96er PCR-Plates Fisher Scientific 
Parafilm Pechiney Plastic Packaging 
Pasteur Pipette Hartenstein 
PCR-Plates (96-well) Fisher Scientific  
Pipetboy  INTEGRA Biosciences  
Pipette tips (10 µl, 20 µl, 100 µl, 200 µl, 1000 µl) Biozym 
Pipettes (0.5-10 µl, 10-100 µl, 100-1000 µl) Gilson 
Scalpels Mergo GmbH & Ko KG 
Stripette (2, 5, 10, 25 and 50 ml) Corning Incorporated 
Needle and syringe for intravenous injection 
(BD MicroFine™+ Insulin) 
BD Biosciences 
Syringes for viruses (0,45μm) (Carl) Roth 
 
3.1.3 Mice strains 
 
Mouse strain Manufacturer 
NSG (NOD.CG-SCID): 
NOD-scid IL2Rgammanull, NOD-scid IL2Rgnull, NSG, NOD scid 
gamma 
The Jackson Laboratory 
NOD/SCID: 
NOD/MrkBomTac-Prkdcscid 
Taconia Denmark ApS 
 
3.1.4 Instruments and equipment 
 
Device Specification Manufacturer 
Affymetrix-Gene Chip Human Clariom™ D  Thermofischer 
Autoclave Varioklav  HP Laboratortechnik 
Bacteria incubator Kelvitron Heraeus 
Bacteria shaker Certomat IS Braun BioTech internat. 
Bioanalyzer 2100 Agilent Technologies 
Cell counter Countess II Thermofischer 
Centrifuge Heraeus™ Megafuge™ 40 Heraeus  
Centrifuge Centrifuge (5424 R and 5430) Eppendorf 
Controlled-freezing box Mr. Frosty Nalgene 
Electrophoresis Mini Trans-Blot Biorad 
ELISA reader Varioskan™ LUX Thermofisher 
Flow Cytometer BD Accuri™ C6  BD Biosciences 
Freezer (-20°C) No Frost Siemens 
Freezer (-80°C) B 35-50 Fryka 
Gel documentation Multi Image Light Cabinet  Alpha Innotech 
Hemocytometer C-Chip Biochrom 
Ice maker SPR 80 Nordcap 
Incubator Heracell™ 240i CO2 incubator Thermofisher 
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Luminometer Orion II  Berthold 
Microscope (fluorescence) Axiovert200 Zeiss 
Microscope (TMA) Axioplan 2 imaging Zeiss 
Multichannel pipette Transferpette-12 electronic Brand 
Nanodrop Nanodrop ND-1000 UV/Vis Thermofischer 
pH-meter pH-197 WtW 
Power Supply PowerPac™  Biorad 
RT-qPCR software Bio-Rad CFX Connect™ Biorad  
Scale GE1302 Sartorius 
SDS-PAGE chamber Mini Trans-Blot Biorad 
Shaker Unimax 1010 DT Heidolph Instruments 
Sterile bench Maxisafe2020 Thermofisher 
Thermocycler T100 TM Thermal Cycler Biorad 
Thermomixer Thermomixer comfort Eppendorf  
Vortex Vortex-Genie 2 Scientific Industries 
Waterbath ED-5 Julabo 
Western blot documentation Image Studion Ver 5.2 LI-COR 
 
3.1.5 Chemicals 
 
Chemicals Manufacturer 
Acrylamid/Bisacrylamid (Carl) Roth 
Agar Sigma-Aldrich 
Agarose Sigma-Aldrich 
Ammonium Perisulfate (APS) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Atipamezole hydrochloride Prodivet pharmaceuticals 
BelaDox® Bela-pharm 
Bovine albumin (BSA) Sigma-Aldrich 
Buprenorphin hydrochloride Richter Pharma AG 
BRD56491 Sigma-Aldrich 
Cumate solution  System Biosciences 
DC_AC50 Sigma-Aldrich 
Dimethylsulfoxid (DMSO) Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Doxycycline Hyclate (HPLC) Sigma-Aldrich 
Elesclomol (STA-4783) Selleckchem 
Ethanol (99%) (Carl) Roth 
Fentanyl Dechra Veterinary Products 
Glacial acetic acid Sigma-Aldrich 
Glycine (Carl) Roth 
H202 30% (w/w) Sigma-Aldrich 
H2DCFDA (DCF-DA) Invitrogen 
Isopropanol (Carl) Roth 
L-glutamine Sigma-Aldrich 
LB-Medium (Carl) Roth 
Menadione Sigma-Aldrich 
Midazolam Roche  
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Medetomidin hydrochlorid Prodivet pharmaceuticals 
Methanol (100%) (Carl) Roth 
Milk powder (Carl) Roth 
MitoSOX Red and MitoTracker green Thermofisher 
N-acetylcysteine (Nac) Sigma-Aldrich 
Naloxon hydrochloride B. Braun Melsungen AG 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Resazurin Sigma-Aldrich 
Sodium Chloride (NaCl) (Carl) Roth 
Sodium Deoxycholate Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Sodium Orthovanadate (Na3VO4) Sigma-Aldrich 
Target Retrieval Solution Agilent Technologies 
TEMED Sigma-Aldrich 
Tiron (disodium 4,5-dihydroxy-1,3-
benzenedisulfonate) 
Sigma-Aldrich 
TRIS-Base Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
Tween-80 Sigma-Aldrich 
 
3.1.6 Biological reagents 
 
Reagents Manufacturer 
1-kbp DNA-ladder  (Carl) Roth 
4% Formalin Sigma-Aldrich 
Accutase Sigma-Aldrich 
AEC+ Substrate-Chromogen Agilent Technologies 
AgeI-HF New England BioLabs 
β-FGF Life Technologies  
Bradford reagent Biorad 
Crysatl violet Sigma-Aldrich 
DAB+ Substrate-Chromogen Agilent Technologies 
Deoxynucleotide triphosphates (dNTPs) Sigma-Aldrich 
Dh5α competent cells Thermofisher  
DMEM with 3.7 g/l NaHCO3, with 1.0 g/l D-glucose Biochrom 
Ethidiumbromide Sigma-Aldrich 
EcoRV-HF New England BioLabs 
Fetal bovine serum (Tetracycline-free) Sigma-Aldrich 
Geltrex LDEV-Free Reduced Growth Factor 
Basement Membrane Matrix 
Thermofisher 
GeneRuler 100 bp Plus DNA Ladder Life Technologies 
GoTaq G2 Hot Start Polymerase  Promega 
Hematoxylin Vector Laboratories 
Hexadimethrinbromide (polybren) Sigma-Aldrich 
HindIII-HF New England BioLabs 
HiPerFect Qiagen  
Immobilon Western HRP Substrate Merck  
Lipofectamine LTX Reagent with PLUSReagent Invitrogen 
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Lipofectamine LTX with Plus Reagent Thermofisher 
Lipofectamine RNAiMax  Invitrogen 
Maxima Hot Start Taq DNA Polymerase Thermo Scientific 
Maxima Hot Start Taq Polymerase Thermo scientific 
Opti-MEM Medium Life Technologies 
PageRuler Prestained Protein Ladder Thermofisher 
Penicillin/Streptomycin  Biochrom  
Penicillin-Streptomycin-Glutamine (100x) Life Technologies 
Phosphate Buffered Saline (PBS) Biochrom 
Phusion High-Fidelity DNA Polymerase Thermo Scientific 
Plasmocure InVivoGen 
Poly-Ethylene-Glycol (PEG) Sigma-Aldrich 
Propidium-iodide Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
Puromycin InVivoGen 
Quick Start Bovine Serum Albumin Standard Biorad  
Beetle- and Renilla-Juice PJK 
Streptavidin HRP Leica Biosystems 
RNase Thermofisher 
RPMI 1640 with 2.0 g/l NaHCO3 500 ml Biochrom 
Sipool  BIOTECH (siTools) 
Stellar competent cells  Takara 
Sucrose > 99.5% (GC) Sigma-Aldrich 
SYBR SELECT Master Mix  Life Technologies 
T4 Ligase  Thermo Scientific 
Target Retrieval Solution Agilent Technologies 
Trypanblue Sigma-Aldrich 
Trypsin/EDTA (10x) Biochrom 
XhoI Thermo Scientific 
α-Medium (no nucleosides) Biochrom 
ProTaqs II Antigen Enhancer Quartett Biochemicals 
 
3.1.7 Commercial kits 
 
Kit Manufacturer Reference 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel 740609 
ReliaPrep miRNA Cell and Tissue Miniprep System Promega Z621 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814 
NucleoSpin RNA  Macherey-Nagel 740955 
NucleoSpin Tissue/DNA  Macherey-Nagel 740952 
In-Fusion HD Cloning Kit  Takara 639646 
PureYield Plasmid Midiprep System Promega A2495 
FITC Annexin V Apoptosis Detection kit I BD Biosciences  556547 
ImmPRESS HRP anti-rabbit IgG Polymer Detection Kit  Vector Laboratories MP-7401 
ImmPRESS HRP Anti-Mouse IgG IgG Polymer 
Detection Kit 
Vector Laboratories MP-7402 
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3.1.8 Restriction enzymes 
 
Name Sequence (5’→3’) Manufacturer Reference 
XhoI-HF (20U) CTCGAG New England BioLabs R0146S 
EcoRV-HF (20U) GATATC New England BioLabs R3195S 
HindIII-HF (20U) AAGCTT New England BioLabs R3104S 
AgeI-HF (20U) ACCGGT New England BioLabs R3552S 
EcoRI-HF (20U) GAATTC New England BioLabs R3101S 
NotI-HF (20U) GCGGCCGC New England BioLabs R3189S 
AvrII-HF (5U) CCTAGG New England BioLabs R0174S 
SbfI-HF (10U) CCTGCAGG New England BioLabs R3642S 
BamHI-HF (20U) GGATCC New England BioLabs R3136S 
PacI-HF (10U) TTAATTAA New England BioLabs R0547S 
 
3.1.9 Primary and Secondary antibodies for Western blot and immunohistochemistry 
3.1.9.1 Western blot 
 
Antibody Manufacturer Reference 
Mouse monoclonal anti-GAPDH Santa Cruz Sc-32233 
Mouse monoclonal anti-SOX6 Santa Cruz Sc-393314 
Goat polyclonal anti-rabbit IgG-HRP OriGene EU  R1364HRP 
Goat polyclonal anti-mouse IgG(H+L)-HRP Promega W402B 
Rabbit monoclonal anti-TXNIP Abcam ab188865 
 
3.1.9.2 Immunohistochemistry  
 
Antibody Manufacturer Reference 
Rabbit polyclonal anti-SOX6  Atlas Antibodies HPA003908 
Rabbit monoclonal anti-Ki67 Cell marque 275R-15 
Mouse monoclonal anti-8-OHG OriGene Technologies AM03160PU-N 
Rabbit polyclonal anti-Cleaved Caspase 3 Cell Signaling 9661 
Rabbit monoclonal anti-TXNIP Abcam ab188865 
Biotinylated anti-rat IgG mouse adsorbed Vector Laboratories BA 4001 
 
3.1.10 Buffer and solutions 
 
Solution Composition 
10× RIPA Buffer 
150 mM NaCl; 1% triton X-100; 0.5% sodium deoxycholate; 
0.1% SDS; 50 mM Tris-HCl, pH = 8 
Freezing solution 10% DMSO, 45% FCS and 45% normal medium 
1× TBS  100 ml 10× TBS; 900 ml H2O 
1× TBST 100 ml 10× TBS; 900 ml H2O; 1 ml Tween-20 
10× Running/Blotting buffer (10× 
R/B buffer) (pH = 8.3) 
30g Tris-Base; 144g glycine 
1× Running buffer 100 ml 10× R/B buffer; 900 ml H2O; 10 ml 10% SDS 
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1× Blotting buffer 100 ml 10× R/B buffer; 700 ml H2O; 200 ml methanol 
Loading dye 
312.5 mM Tris-HCl (pH = 6.8); 10% SDS; 50% glycerol; 
bromphenolblue 
4× Loading dye 250 mM DTT to 1 ml loading dye 
10% SDS 10g SDS; 100 ml H2O 
Blocking buffer 5% non-fat dried milk or 5% BSA in 1x TBST  
10% APS 1g ammonium persulfate; 10 ml H2O 
Na3VO4 (pH = 10) 200 mM Na3VO4  
10× annealing buffer 1 M NaCl, 100 mM Tris-HCl, pH = 7.4 
RPMI medium 
500 ml RPMI 1640 medium, 10% FCS, 1% 
Penicillin/Streptomycin (P/S) 
DMEM medium 500 ml DMEM medium, 10% FCS, 1% P/S 
α-medium 500 ml α-medium, 10% FCS, 1% P/S, 2 ng/ml β-FGF 
10× TAE electrophoresis buffer 
48.4g Tris-Base, 11.4 ml glacial acetic acid, 3.7g EDTA, fill 
up to 1L with H2O 
Electrophoresis gel 100 ml 1× TAE buffer, X% agarose, 4 µl EtBr 
10× TBS (pH = 7.3) 24g Tris-Base; 88g NaCl 
1 M Tris-HCl; pH = 6.8  30.3g Tris up to 250 ml H2O 
1.5 M Tris-HCl; pH = 8.8 45.4g Tris up to 250 ml H2O 
 
3.1.11 SDS-PAGE gel compositions 
 
Resolving gel (7.5 ml) 5% 7% 10% 12% 
H2O 4.2 ml 3.7 ml 2.9 ml 2.4 ml 
1.5 M Tris-HCl (pH = 8.8) 2 ml 2ml 2ml 2ml 
30% (w/v) Acrylamid/Bisacrylamid 1.3 ml 1.8 ml 2.5 ml 3 ml 
10% (w/v) SDS 75 µl 75 µl 75 µl 75 µl 
10% (w/v) APS 40 µl 40 µl 40 µl 40 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 
 
Stacking gel (5ml) 3% 
H2O 3.5 ml 
1 M Tris-HCl (pH = 6.8) 860 µl 
30% (w/v) Acrylamid/Bisacrylamid 500 µl 
10% (w/v) SDS 48 µl 
10% (w/v) APS 40 µl 
TEMED 10 µl 
 
3.1.12 Sequences 
3.1.12.1 shRNA sequences for pLKO-Tet-On cloning 
 
Oligoname Hairpin sequence (5’ → 3’) TRCN-Number 
sh_Control 
top 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCT
TCATCTTGTTG 
 
sh_Control 
bottom 
AATTCAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGG
TGCTCTTCATCTTGTTG 
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shRNA_SOX6_1 
top 
CCGGCCAGCCCTGTAACTCAAGTTACTCGAGTAACTTGAGTT
ACAGGGCTGGTTTTTG 
0000085945 
shRNA_SOX6_1 
bottom 
AATTCAAAAACCAGCCCTGTAACTCAAGTTACTCGAGTAACT
TGAGTTACAGGGCTGG 
 
shRNA_SOX6_2 
top 
CCGGCCAGTGAACTTCTTGGAGAAACTCGAGTTTCTCCAAGA
AGTTCACTGGTTTTTG 
0000017990 
shRNA_SOX6_2 
bottom 
AATTCAAAAACCAGTGAACTTCTTGGAGAAACTCGAGTTTCT
CCAAGAAGTTCACTGG 
 
shRNA_SOX6_3 
top 
CCGGTGGTCTTAATTGTTTCGTAAACTCGAGTTTACGAAACA
ATTAAGACCATTTTTG 
0000430184 
shRNA_SOX6_3 
bottom 
AATTCAAAAATGGTCTTAATTGTTTCGTAAACTCGAGTTTAC
GAAACAATTAAGACCA 
 
 
3.1.12.2 Sequences for pCDH vector cloning 
 
Oligoname Sequence (5’ → 3’) 
dsDNA 
GCTAGCCCTAGGCCTGCAGGGAATTTAAATCGGATCCTTAATTAAGGATCTGCGAT
CGC 
 
3.1.12.3 Primer 
 
 
 
 
Oligoname Sequence (5’ → 3’) 
RPLPO_FW GAAACTCTGCATTCTCGCTTC 
RPLPO_RV GGTGTAATCCGTCTCCACAG 
SOX6_FW TTCCCCGACATGCATAACTC 
SOX6_RV AAGTGGATCTTGCTTAGCCG 
pGL3_mSat_FW CTAGCCCGGGCTCGAGGAGATGTGTCAGCAGTCAATCCA 
pGL3_mSat_RV GATCGCAGATCTCGAGGGCAGTCCAGGATGTTCTGAATAA 
E2F8_FW ACAGAATGGAGAACGAAAAGGA 
E2F8_RV TTGGTAGGTGTGGTTAAAGGG 
DEPDC1_FW GGCCAATACAAGTAAACGTGG 
DEPDC1_RV CATCTCGTTCAAATCCAACATAAGT 
CDCA3_FW ACTGGAGGGTCTTAAACATGC 
CDCA3_RV ACTTCACTCAGCTGTTTCACC 
Tet-pLKO_FW GGCAGGGATATTCACCATTAT 
Tet-pLKO_RV CTATTCTTTCCCCTGCACTG 
TXNIP_FW GATCTGAACATCCCTGATACCC 
TXNIP_RV CATCCATGTCATCTAGCAGAGG 
eGFP_FW ATTAGAATTCATGGTGAGCAAGGGCGAG 
eGFP_RV ATTAGCGGCCGCTTACTTGTACAGCTCGTCCATGC 
cDNA TXNIP_FW ATTAGCTAGCGCCACCATGGTGATGTTCAAGAAGATCAAGTC 
cDNA TXNIP_RV GCGGCGTTAATTAATCACTGCACATTGTTGTTGAGG 
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3.1.12.4 Sequencing primer 
 
Name Sequence (5’ → 3’) 
RVprimer3 CTAGCAAAATAGGCTGTCCC 
GLprimer2 CTTTATGTTTTTGGCGTCTTCCA 
pLKOseq_FW GGCAGGGATATTCACCATTATCGTTTCAGA 
pLKOseq_RV GACGTGAAGAATGTGCGAGA 
pCDH_FW ATGGTGATGTTCAAGAAGATCAAGTC 
pCDH_RV AAAGCCTTCACCCAGTAGTC 
 
3.1.12.5 Sequences for small interfering RNAs (siRNA) 
 
Name Sequence (5’ → 3’) 
siCtrl No sequence given 
siTXNIP  
(sense) 
AAGCCGUUAGGAUCCUGGCdTdT 
siTXNIP (antisense) GCCAGGAUCCUAACGGCUUdTdT 
 
3.1.13 Vectors 
 
Vector name Number Manufacturer 
Tet-pLKO-puro # 21915 Addgene 
pGL3-Promotor Vector # E1761 Promega 
pRL Renilla Vector # E2231 Promega 
pCD/NL-BH*DDD (pol, gag) # 17531 Addgene 
pCEF-VSV-G (env) # 41792 Addgene 
cDNA TXNIP ORF clone 
(NM_006472.5) 
# OHu20973 GenScript 
pCAG-YFP # 11180 Addgene 
pCMV-GFP # 11153 Addgene 
pCDH-Cuo-MCS-EF1-CymR-T2A-
Puro 
# QM800A-1 System Biosciences 
 
3.1.14 Software 
 
Software Manufacturer 
Bio Rad CFX Manager 3.1 Biorad  
GraphPad PRISM 5 GraphPad 
Image J www.rsbweb.nih.gov/ij/ 
Image Studio Lite  LI-COR  
BD Accuri C6 Software BD Biosciences 
GSEA Broad Institute 
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3.2 Methods 
3.2.1 Microbiology 
3.2.1.1 Cloning with the pGL3-Promotor vector 
In order to verify if EWSR1-FLI is binding GGAA-mSats in the intron 1 of the SOX6 gene and thereby 
using these GGAA-mSats as enhancer to trigger SOX6 expression, a 1-kb fragment including the mSat 
and its flanking regions (–/+ 500 bp) were investigated more closely.  
For this experiment the “In-Fusion HD cloning” method was used according to the manufacturer’s 
protocol. In contrast to a classical ligation method, this method is based on recombination of the insert 
with the linearized backbone.  
Primers were specifically designed according to the manufacturer’s protocol including 
15 bp-overhangs that are homologous to the backbone containing the desired insert. Once the inserts 
were amplified with the specific overhangs, recombinase enzymes enable the fusion of the insert into 
the backbone. The pGL3-Promotor vector was used as a backbone that is suitable for cloning and 
testing putative enhancer regions like the GGAA-mSats and its flanking regions. 
The pGL3-Promotor vector (1 µg) was linearized with the restriction enzyme XhoI (1 µl) overnight at 
37°C as given in Table 3. The genomic DNA (gDNA) was extracted from three EwS cell lines with high- 
(RDES, TC-32 and POE), three with intermediate- (EW17, ORS and SK-N-MC), and two with low-SOX6 
expression (A673 and EW7) using the NucleoSpin Tissue Kit. Afterwards, 5 µg of gDNA were digested 
to smaller fragments of ~ 1-kb including the desired GGAA-mSat of the SOX6 gene to facilitate 
subsequent amplification using the restriction enzymes EcoRV (2.5 µl) and HindIII (2.5 µl) as shown in 
Table 3. Here, it was important to choose restriction enzymes that do not cut in the region where the 
GGAA-mSat is supposed to be. Both, the linearized pGL3-Promotor vector and the mSat-amplicon were 
cleaned with the NucleoSpin PCR and Gel clean up kit. 
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Components Amount (µl) 
1 µg pGL3-Promotor vector/ 5 µg gDNA x 
10× CutSmart buffer 10 
Restriction enzyme 1  1 
(Restriction enzyme 2)  (1) 
dH2O Up to 50 µl 
Table 3: Digestion protocol of pGL3-Promotor vector and gDNA. 
 
Specific primers were designed for “In-Fusion HD cloning” including following characteristics:  
1) The 5’–end of the primer must contain 15 bases that are homologous to 15 bases of the 
pGL3-Promotor vector linearized with XhoI to which it will be joined afterwards. The primers were 
designed to include the restriction site for XhoI.  
2) The 3’–end of the primer must contain the sequence that is specific to the genomic GGAA-mSat 
region (see below). 
3) The melting temperature (Tm) of the primer that contains XhoI-site and the beginning of the GGAA-
mSat region need to be between 57–65°C. If not the Tm is considered as 58°C.  
4) The last five nucleotides at the 3’–end of each primer should not contain more than two guanines 
or cytosines. Therefore, the primers were designed based on the sequence for GGAA-mSat region that 
was extracted from the reference genome (see list 8.1). 
The desired mSat-amplicon was amplified from pre-digested gDNA with the corresponding primer 
(see 3.1.12.3) as described in Table 4. 
Components Amount (µl) 
5× Gotaq colorless buffer 10 
10 mM dNTPs 1 
25 mM MgCl2 6 
10 µM pGL3_mSat-FW 2.5 
10 µM pGL3_mSat-RV 2.5 
Gotaq polymerase 0.25 
200 ng gDNA x 
dH2O = up to 50 
Table 4: Protocol for Gotaq PCR-amplification from gDNA. 
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The PCR program (Table 5) included a touch-down (TD) PCR to avoid amplifying non-specific 
sequences. The corresponding Tm for the TD-PCR was calculated as follows:  
1) Tm of primer mix – 5°C (GoTaq Polymerase requirements) – 10°C (decrease of 0.5°C for the 1st 
20 cycles): 
62°C (Tm) – 5°C = 57°C – 10°C (20 cycles with a decrease of 0.5°C) = 47°C *.  
2) The annealing temperature in the 2nd 20 cycles was chosen based on the actual Tm of the primer 
(57°C) **. 
 
Step °C Time Cycles 
Initialization 95 2 min 1 
Denaturation 98 10 sec 
1st 
20 
Annealing 57 – 47* 30 sec 
Elongation 72 1 min 
Denaturation 98 10 sec 
2nd 
20 
Annealing 57** 30 sec 
Extension 72 1 min 
Final Extension 72 ∞  
Table 5: Thermal cycling conditions for Gotaq-mediated mSat-PCR-amplification. 
 
The mSat-amplicon was purified with the NucleoSpin PCR and Gel clean up kit. According to the 
manufacturer’s protocol of the In-Fusion HD cloning, 20 ng of the mSat-fragment and 10 ng of the 
linearized pGL3-Promotor vector were incubated for 15 min at 50°C. Further controls were also 
included (Table 6).  
 
Components Sample Pos. Ctrl Neg. Ctrl 
20 ng DNA  x µl mSat-fragment 2 µl control insert - 
pGL3 backbone  
1 µl (10 ng) linearized 
pGL3 vector 
1 µl PUC19 
linearized vector 
1 µl (10 ng) linearized 
pGL3 vector 
Premix 2 µl 2 µl 2 µl 
dH2O x µl 5 µl 7 µl 
Table 6: “In-Fusion HD cloning” reactions according to manufacturer’s protocol.  
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The reaction was stopped by incubation on ice for 5 min. For amplification of the plasmid see 
section 3.2.1.4. The cloned pGL3-mSat vector with a representative mSat is depicted in Figure 2. 
 
 
Figure 2: The pGL3-mSat plasmid with the pGL3-Promoter vector as backbone and the microsatellite 
(mSat).  
AmpR promoter: expression of the ampicillin resistance; AmpR: ampicillin resistance in E.coli; ori: 
origin of plasmid replication in E.coli; f1 ori: origin of replication derived from filamentous phage; poly 
(A) signal: stabilization of mRNA; mSat: cloned GGAA-mSat region; SV40 promoter: expression of 
cloned DNA in mammalian cells; luciferase: cDNA encoding firefly luciferase; SV40 poly (A) signal: 
terminator sequence. 
 
 
 
 
 
 
 
 
Methods 
 
28 
 
3.2.1.2 Cloning with the pLKO-Tet-On system 
In order to perform long-term analyses, EwS cell lines were transduced with the lentiviral Tet-pLKO-
puro vector containing the pLKO-Tet-On system as described and reviewed in (Das et al., 2016).  
The Tet-ON system is under control of the tetracycline analog Doxycycline (Dox) that induces the 
transcription of small hairpin RNA (shRNA) against the SOX6 gene in order to silence gene expression 
through RNA-interference. The cloning with the Tet-pLKO-puro vector was performed according to 
Wiederschain’s protocol (Wiederschain et al., 2009) deposited at Addgene (Plasmid # 21915).  
The shRNA of the Tet-pLKO-puro vector was designed as described in Table 7 including the restrictions 
sites AgeI, XhoI and EcoRI. The sequences for the shRNA against SOX6 were taken from the “Genetic 
Perturbation Platform (GPP) Web Portal” from the Broad institute. They were designed to form a 
hairpin with top and bottom strand. The shControl, in contrast, was randomly generated (Table 7). 
 
 
AgeI 
Target 
sequence 
XhoI 
Target  
sequence 
Term. 
signal 
EcoRI  
shSOX6_1:  
Top CCGG 
CCAGCCCTGTAAC
TCAAGTTA 
CTCGAG 
TAACTTGAGTTAC
AGGGCTGG 
TTTTTG  
 
TAACTTGAGTTAC
AGGGCTGG 
CTCGAG 
CCAGCCCTGTAAC
TCAAGTTA 
CAAAAA AATT bottom 
shSOX6_2: 
Top CCGG 
CCAGTGAACTTCT
TGGAGAAA 
CTCGAG 
TTTCTCCAAGAAG
TTCACTGG 
TTTTTG  
 
TTTCTCCAAGAAG
TTCACTGG 
CTCGAG 
CCAGTGAACTTCT
TGGAGAAA 
CAAAAA AATT bottom 
shSOX6_3: 
Top CCGG 
TGGTCTTAATTGT
TTCGTAAA 
CTCGAG 
TTTACGAAACAAT
TAAGACCA 
TTTTTG  
 
TTTACGAAACAAT
TAAGACCA 
CTCGAG 
TGGTCTTAATTGT
TTCGTAAA 
CAAAAA AATT bottom 
shControl: 
Top CCGG 
CAACAAGATGAA
GAGCACCAA 
CTCGAG 
TTGGTGCTCTTCA
TCTTGTTG 
TTTTTG   
 
TTGGTGCTCTTCA
TCTTGTTG 
CTCGAG 
CAACAAGATGAA
GAGCACCAA 
CAAAAA AATT bottom 
Table 7: Design of shRNAs against SOX6 or control. 
 
The Tet-pLKO-puro vector was double digested with the corresponding AgeI and EcoRI restriction 
enzymes according to Table 8: 
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Components Amount (µl) 
10× CutSmart buffer  2 
Restriction enzyme 1  2 
Restriction enzyme 2  2 
4 µg Tet-pLKO-puro vector x 
dH2O Up to 20 
Table 8: Double digestion protocol. 
First, the reaction was incubated for 15 min at 37°C and deactivated at 65°C for 20 min. Both digestions 
were pooled to increase the yield. The linearized vector backbone (= 20 µl) was precipitated by adding 
180 µl of water and 20 µl of 3 M sodium acetate (corresponding 1/10 from total volume of 200 µl). The 
mixture was incubated for 45 min at −80°C and afterwards centrifuged at 4°C for 30 min at 13,000 rpm. 
The pellet was washed with 70% ethanol and then centrifuged at 13,000 rpm for 15 min at 4°C. After 
drying the pellet for 2 min at 37°C it was reconstituted with 10 µl dH2O. Verification of the linearized 
Tet-pLKO-puro vector occurred via gel (expected band at 1800 bp for the stuffer and ~8800 bp for 
linearized backbone). 
In a second step, shRNA was annealed before ligation. Therefore, the designed top- and bottom-
shRNAs were both reconstituted with dH2O to 100 µM (0.1 nmol/µl) and 11.25 µl of each oligo was 
mixed together with 2.5 µl of 10× annealing buffer to a final concentration of 0.8 µg/µl each. The 
annealing program was set up as follows: The initial temperature was set to 95°C. Subsequently, the 
temperature was decreased by one degree/minute until 14°C was reached to ensure proper annealing 
of top- and bottom-strand. Afterwards, 1 µl of the oligo mixture was diluted 1:400 with 0.5× annealing 
buffer to a final concentration of 200 ng/µl. 
In a third step, ligation of the 58 bp-annealed shRNA and double-digested and precipitated Tet-pLKO-
puro vector was performed overnight at 16°C as described in Table 9: 
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Components Amount (µl) 
20 – 30 ng/µl  
linearized Tet-pLKO-puro 
1 
200 ng annealed shRNA 1 
10× Ligase buffer 1.5 
T4 DNA Ligase 1 
dH2O  up to 15 
Table 9: Ligation protocol of Tet-pLKO-puro with shRNAs. 
 
The reaction was stopped by incubation on ice for 5 min. For amplification of the plasmid see 
section 3.2.1.4. The cloned pLKO-shSOX6/ (pLKO-shCtrl) vector is depicted in Figure 3. 
 
Figure 3: The pLKO-shSOX6 plasmid with the Tet-pLKO-puro vector as backbone with shRNA against 
SOX6 as insert.  
hPGK promoter: eukaryotic promoter; β-globulin intron: enhancer of the T7 promoter; T7 promoter: 
prokaryotic promoter; TetR: tetracycline resistance; IRES: internal ribosome entry site (simultaneous 
expression of two proteins); PuroR: puromycin resistance; 3’ LTR (∆U3): lentivirus component; SV40 
ori: SV40 promoter origin; SV40 poly (A) signal: terminator sequence; f1 ori: origin of replication 
derived from filamentous phage; AmpR promoter: expression of the ampicillin resistance; AmpR: 
ampicillin resistance in E.coli; ori: origin of plasmid replication in E.coli; CAP binding site: Catabolite 
Activator Protein binding site (facilitates the transcription activation of the lac promoter); 
lac promoter: prokaryotic promoter; lac operator (+1): lac operon; T3 promoter: prokaryotic promoter; 
RSV promotor: Rous Sarcoma Virus (HIV-based eukaryotic promoter); transfer plasmids: 5’LTR, HIV-
1Ѱ, RRE (Rev Response Element), 3’ LTR (∆U3); tet operator: tetracycline-controlled transcriptional 
activation; shSOX6: shRNA against SOX6; cPPT/CTS: increases the viral infectivity in non-dividing cells. 
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3.2.1.3 Cumate-inducible pCDH-CuO-MCS-EF1αCymR-T2A-Puro 
For TXNIP rescue experiments with cumate-inducible TXNIP re-expression in SOX6-silenced TC-32 EwS 
cell lines (Tc-32/TR/shSOX6_2), following cloning strategies were carried out. The ”Cumate-Switch 
System Vector” constitutively co-expresses CymR, a repressor that binds a cumate operator sequence 
in absence of cumate. The “Cumate-Switch System Vector” is able to co-express both the cDNA of 
TXNIP and the eGFP marker combined with a T2A element from the cumate switch promoter. The 
TXNIP expression can be controlled by adding cumate to the cells as the cumate repressor (CymR) has 
a higher binding affinity for cumate (Mullick et al., 2006). The cumate-inducible TXNIP re-expression 
plasmid is based on the pCDH-CuO-MCS-EF1α-CymR-T2A-Puro SparQ™ All-in-one Cloning and 
Expression Lentivector. 
In a first step, the multiple cloning site (MCS) was modified as it was necessary to eliminate the EcoRI 
and NotI restriction sites. Therefore, a customized dsDNA oligonucleotide sequence (Table 10) was 
created, including AvrII, SbfI, BamHI and PacI restriction sites:  
NheI AvrII SbfI 
Random 
sequence 
PacI BamHI AsiSI 
GCTAGC CCTAGG CCTGCAGG 
GAATTTAAATCGG
ATCC 
TTAATTAA GGATCC GCGATCGC 
Table 10: Customized dsDNA (5’→3’).  
 
Both, 1 µg of the dsDNA oligonucleotide sequence and 1 µg of the pCDH vector were double digested 
with NheI and AsiSI overnight at 37°C according to Table 3, and cleaned with the NucleoSpin PCR and 
Gel clean up kit. Subsequently, both the digested pCDH and the dsDNA were ligated by T4 Ligase (Table 
11). The reaction was stopped by incubation on ice for 5 min.  
Components Amount (µl) 
25 ng pCDH vector x  
Insert (dsDNA) – 6:1 ratio x  
10× Ligase buffer 2  
T4 DNA Ligase 1  
dH20  up to 20  
Table 11: Ligation protocol of pCDH vector with dsDNA oligonucleotide sequence. 
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Secondly, as the TC-32/TR/shSOX6_2 cell already contained a puromycin-resistance cassette, the 
puromycin-resistance gene within the pCDH vector was removed by double digestion (Table 8) of the 
pCDH vector with EcoRI and NotI. In order to be able to select the cells that express the cDNA of TXNIP, 
an eGFP reporter protein for co-expression was included. The eGFP sequence was PCR-amplified using 
a pCMV-GFP vector as a template (Table 15) with the following primers (Table 12): 
 
 Start EcoRI Primer sequence (5’→3’) 
eGFP_FW: ATTA GAATTC GCCACCATGGTGATGTTCAAGAAGATCAAGTC 
 
 Start PacI Primer sequence (5’→3’) 
eGFP_RV: ATTA GCGGCCGC TTACTTGTACAGCTCGTCCATGC 
Table 12: Primer for eGFP amplification from pCMV-GFP vector. 
 
The amplicon was purified with the NucleoSpin PCR and Gel clean up kit. In a last step, full-length cDNA 
of TXNIP was PCR-amplified (Table 13 and Table 15) from a cDNA TXNIP ORF clone (see 3.1.13) and 
modified in order to be ligated into the customized MCS. 
 
 Start NheI Primer sequence (5’→3’) 
cDNA TXNIP_FW: ATTA GCTAGC GCCACCATGGTGATGTTCAAGAAGATCAAGTC 
 
 Start PacI Primer sequence (5’→3’) 
cDNA TXNIP_RV: GCGGCG TTAATTAA TCACTGCACATTGTTGTTGAGG 
Table 13: Primer for cDNA TXNIP amplification. 
 
The transgene was then inserted by NheI-PacI double digestion (Table 8), and cleaned with the 
NucleoSpin PCR and Gel clean up kit. For amplification of the plasmid see section 3.2.1.4. The cloned 
cumate-inducible pCDH-TXNIP vector is depicted in Figure 4. 
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Figure 4: Cumate-inducible pCDH-TXNIP vector.   
Lentivirus components: RSV promoter: eukaryotic promoter, transfer plasmids: 5’LTR, HIV-1Ѱ, RRE, 3’ 
LTR (∆U3); packaging plasmids: gag, pol and RRE; envelope plasmid: env; cPPT: increases the viral 
infectivity in non-dividing cells; CMV promoter: eukaryotic promoter; CUO: cumate operator sequence; 
TXNIP: cDNA of TXNIP; EF1 alpha promoter: eukaryotic promoter with constitutive expression; CymR: 
repressor that binds CUO; T2A: enables the simultaneous expression of two proteins; WPRE element: 
enhances stability and translation of the CMV-driven transcript; SV40 ori: SV40 promotor origin; SV40 
poly(A) signal: termination and processing of the recombinant transcript; pUC origin: replication and 
maintenance of the plasmid in E.coli cells; AmpR promoter: expression of the ampicillin resistance; 
AmpR: ampicillin resistance in E.coli. 
 
 
 
3.2.1.4 Transformation of E.coli and colony PCR 
After the cloning strategy of the pGL3-mSat, pLKO-shSOX6 and pCDH-TXNIP vectors, the plasmids were 
transformed into Stellar Competent cells. Therefore, 50 µl of competent cells were quickly thawed on 
ice for 5 min, directly mixed with 5 ng (~ 2.5 µl) of ligation-mixture and incubated for 30 min on ice. A 
heat shock occurred for exactly 45 seconds at 42°C with subsequent 2 min incubation on ice. The 
competent cells were reconstituted with 500 µl of pre-warmed SOC-medium and incubated while 
shaking for 1 h at 37°C. An appropriate amount of transformed bacteria were plated out on ampicillin 
plates (50 − 100 µg/ml) and incubated overnight at 37°C for further selection.  
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The transformation success was verified through the colony touch-down (TD) PCR. At least 20 colonies 
were picked and each incubated in 100 µl LB-Medium containing 100 µg/ml ampicillin for 1h at 37°C. 
The PCR mix was prepared as follows (Table 14): 
 
Components  Amount (µl) 
5× Gotaq colorless buffer 10 
10 mM dNTPs 1 
25 mM MgCl2 6 
10 µM Forward primer*/# 2.5 
10 µM Reverse primer*/# 2.5 
Gotaq polymerase 0.25 
Colony solution 2 
dH2O x 
Total volume  up to 50 
Table 14: Protocol for colony-PCR of pGL3-mSat (*)– and pLKO-shSOX6/shCtrl (#)-insert amplification.  
 
Components Amount (µl) 
5× HiFi buffer 5 
10 Mm dNTPs 1 
100% DMSO 1.5 
10 µM primer mix**/## 2.5 
10 µM primer mix**/## 2.5 
Phusion polymerase 0.5 
100 ng DNA  x 
dH2O  up to 50 
Table 15: Protocol for PCR-amplification of eGFP (**) or cDNA TXNIP (##) from pCMV-GFP or TXNIP ORF 
vector, respectively and protocol for colony-PCR of pCDH-TXNIP-insert (##) amplification. 
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For pGL3-mSat, pLKO-shSOX6/shCtrl, pCMV-GFP or TXNIP ORF vectors the following primers were 
included: 
- pGL3-specific primers*:  
pGL3_mSat_FW: 5’–CTAGCCCGGGCTCGAGGAGATGTGTCAGCAGTCAATCCA–3’; 
pGL3_mSat_RV: 5’–GATCGCAGATCTCGAGGGCAGTCCAGGATGTTCTGAATAA–3’, 
- pLKO-specific primers#:  
Tet-pLKO_FW: 5’–GGCAGGGATATTCACCATTAT–3’; 
Tet-pLKO_RV: 5’–CTATTCTTTCCCCTGCACTG–3’. 
- pCMV-GFP-specific primers**: 
eGFP_FW: 5’–ATTAGAATTCATGGTGAGCAAGGGCGAG–3’; 
eGFP_RV: 5’–ATTAGCGGCCGCTTACTTGTACAGCTCGTCCATGC–3’. 
- cDNA TXNIP ORF/pCDH-specific primers##: 
cDNA TXNIP_FW: 5’–ATTAGCTAGCGCCACCATGGTGATGTTCAAGAAGATCAAGTC–3’; 
cDNA TXNIP_RV: 5’–GCGGCGTTAATTAATCACTGCACATTGTTGTTGAGG–3’. 
The colony-PCR included a touch-down (TD)-PCR (colony-TD-PCR) to increase specificity. This 
possesses a higher initialization time, as it first needs to disrupt the bacterial membrane (Table 16 and 
Table 17): 
Step °C Time Cycles 
Initialization 95 10 min 1 
Denaturation 98 10 sec 
1st 
10 
Annealing X* 30 sec 
Elongation 72 1 min 
Denaturation 98 10 sec 
2nd 
20 
Annealing X** 30 sec 
Extension 72 1 min 
Final Extension 72 ∞ 1 
Table 16: Thermal cycling conditions for colony-TD-PCR of pLKO-Tet and pGL3 vectors.  
X*:The annealing temperature for the 1st 10 cycles needs to be adapted to the corresponding Tm of the 
constructs: For pGL3_mSat vector: Tm = 57°C – 47°C; for pLKO_shSOX6/shCtrl vector: Tm = 67°C – 57°C. 
X**: The annealing temperature for the 2nd 20 cycles is the actual Tm of the constructs: For pGL3_mSat 
vector: Tm = 57°C; For pLKO_shSOX6/shCtrl vector: Tm = 67°C. 
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Step °C Time Cycles 
Initialization 98 3 min 1 
Denaturation 98 10 sec 
 
1-10 
 
Annealing 
69 – 0.5 per 
cycle 
30 sec 
Elongation 72 25 sec/ 1kb 
Denaturation 98 10 sec  
11-25 
 
Annealing 64 30 sec 
Extension 72 25 sec/ 1kb 
Final Extension 72 5 min 1 
Table 17: Thermal cycling conditions for (colony)-TD-PCR for pCMV-GFP/ TXNIP ORF vector and pCDH-
TXNIP vectors. 
 
The colony-PCR was loaded on an agarose gel to see if the picked colonies include the correct insert: 
mSat = 866 bp, shSOX6/shCtrl insert = 420 bp, eGFP = 720 bp, cDNA TXNIP = 1.2 kbp.  
The selected candidates were cultivated in a 100 ml midi-culture (including 100 µg/ml ampicillin) at 
37°C overnight. The plasmids were extracted with the PureYield Plasmid Midiprep System according 
to the manufacturer’s protocol and re-suspended in 40 µl dH2O. 
 
3.2.1.5 Sequencing of pGL3-mSat, pLKO-shSOX6/shCtrl and pCDH-TXNIP constructs 
In order to exclude point mutations that could have occurred during transformation with E.coli, 
sequencing was performed. Thereby the sequencing-primers (see 3.1.12.4) were diluted to 10 µM and 
the plasmid to 50 ng – 100 ng in 30 µl total volume.  
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3.2.2 Cell culture 
3.2.2.1 Cell lines 
In this thesis the following cell lines were used: 
• EwS cell lines  
A673, MHH-ES1, RDES, SK-N-MC, CHLA-10, CHLA-25, CHLA-32, CHLA-57, CHLA-99, COG-E-352, RH-1, 
TC-32, TC-71, TC-106, ES7, EW1, EW3, EW7, EW16, EW17, EW18, EW22, EW24, ORS, POE, SK-PN-DW, 
SK-PN-LI, SK-ES1, MIC and STA-ET1. 
• Neuroblastoma cell lines 
SK-N-AS and TGW. 
• Rhabdomyosarcoma cell lines  
Rh4 and Rh36. 
• Osteosarcoma cell lines  
SAOS-2 and U2OS. 
• MSC-52 (From bone marrow of an EwS patient) 
• HEK-293 (Human embryonic kidney cell line) 
 
The A673/TR/shEF1 and SK-N-MC/TR/shEF1 cell lines used in this thesis were kindly provided from Dr. 
med. Martin Orth. 
The following four cell lines were mainly used in this thesis (Table 18): 
Cell line Description 
A673 
EwS cell line (type 1 translocation) established from the primary tumor 
of a 15-year-old girl (Giard et al., 1973) 
RDES 
EwS cell line (type 2 translocation) established from the primary tumor (humerus) of a 
19-year-old man 
TC-32 
EwS cell lines (type 1 translocation) isolated from the iliac bone and adjacent soft 
tissue of a 17 years old female before chemotherapy treatment (May et al., 2013) 
POE EwS cell lines (type 1 translocation) established at the Institute Curie, Paris. 
Table 18: Origin of the mostly used EwS cell lines. 
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3.2.2.2 Cell culture methods 
All EwS, neuroblastoma, rhabdomyosarcoma, osteosarcoma cell lines as well as the HEK-293 cell line 
were cultured in RPMI-1640 medium with stable glutamine supplemented with 10% tetracycline-free 
fetal calf serum (FCS) and 100 U/ml Penicillin and 100 µg/ml Streptomycin (P/S) at 37°C with 5% CO2 in 
a humidified atmosphere. The patient-derived mesenchymal stem cell line (MSC-52) was cultivated in 
α-Medium supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (P/S), 10% FCS and 
2 ng/ml β-FGF at 37°C with 5% CO2.  
EwS cell lines were transduced with corresponding shRNA and selected with 1.5 µg/ml puromycin for 
a period of time. 
About 1 × 106 cells/ml were frozen in liquid nitrogen for long-term storage by adding a freezing solution 
to the cell pellet. The cells were defrosted in a water bath at 37°C and re-suspended in 5 ml culture 
medium to eliminate DMSO. Subsequently, the cells were centrifuged at 1,200 rpm for 5 min and the 
supernatant was discarded. The pellet was re-suspended in an appropriate volume of medium and 
transferred to T75 cm2 flask. The splitting of the cells was carried out by previous washing of the cells 
with PBS and subsequent trypsinization to dissolve the adherence boundaries of the cells. The cell lines 
were routinely tested for mycoplasma contamination by nested PCR, and the cell line identity was 
regularly verified by Short Tandem Repeat (STR)-profiling. 
 
3.2.2.3 Transduction of pLKO-shSOX6 and pLKO-shSOX6-pCDH-TXNIP in EwS cell lines 
For long-term experiments RDES, POE and TC-32 cell lines were transduced with the Tet-pLKO-shSOX6 
vector or additionally transduced with the pCDH-TXNIP vector.     
For lentiviral transduction of EwS cell lines, 3 × 105 HEK-293 cells/T75 flask were cultured with 10 ml 
RPMI medium containing 10% FCS and 1% P/S for 72h. In order to increase safety levels of lentiviruses, 
the packaging plasmids were added separately to the plasmids containing the DNA. Therefore, 10 µg 
DNA plasmid of pLKO_shSOX6 or pCDH-TXNIP was added to 10 µg ∆8.9 (containing gag and pol) and 
3 µg VSV-G (containing env) up to 4.6 ml of OptiMEM. Subsequently, 46 µl of Plus Reganet was added 
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to the mixture, incubated for 10 min at RT and then 60 µl of Lipofectamine LTX were incubated for a 
further 25 min at RT. Thereafter, 4.4 ml of the transfection reaction were added to HEK-293 cells in 10 
ml medium, that was replaced with a completely fresh medium after 4h of incubation in order to 
reduce toxicity. 24h after transfection, the medium was replaced with 30% FCS-containing medium to 
accelerate virus production.  
At the same time 2 × 105 cells/ 6-well were pre-cultured in a total volume of 1.7 ml RPMI medium. 48h 
after transfection, the virus-containing supernatant was filted thorugh a 0.45 µm filter in order to 
exclude cell contamination with HEK-293 cells. Depending on the construct, 500 µl of the 
virus-containing supernatant was added to the pre-cultured cells for 72h. Subsequently, EwS cells 
transduced with pLKO_shSOX6 or pLKO-shSOX6-pCDH-TXNIP respectively, were washed twice with 
PBS and further selected with medium containing 1 µg/ml puromycin for at least 1 week. Additionally, 
pLKO-shSOX6-pCDH-TXNIP vectors were sorted by eGFP-positive cells.  
The resulting EwS cell lines were called: TC-32_shCtrl, TC-32_shSOX6_2, TC-32_shSOX6_3, 
RDES_shCtrl, RDES_shSOX6_2, RDES_shSOX6_3, POE_shCtrl, POE_shSOX6_1, POE_shSOX6_3 or 
TC-32_shSOX6_2_pCDH-TXNIP. 
 
3.2.2.4 Transfection 
For RNA interference experiments A673, EW7, RDES, TC-32 and POE cell lines were transiently 
transfected with Lipofectamine RNAiMAX (see 3.2.5.1). Transfection of the pGL3_mSat vector into 
A673/TR/shEF1 cells as well as the pLKO_shSOX6 vector and the pCDH-TXNIP vector into HEK-293 cells 
was performed with Lipofectamine LTX with Plus Reagent according to the manufacturer’s protocol if 
not otherwise specified.  
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3.2.3 Molecular biology 
3.2.3.1 Isolation of total RNA, cDNA synthesis and quantitative real time PCR (qRT-PCR) 
 
The total RNA was isolated from cell lines and tumor tissue using the NucleoSpin RNA kit. Afterwards, 
1 µg of total RNA was reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit as 
follows (Table 19): 
 
Components Amount (µl) 
10× RT buffer 2 
10× RT random primers 2 
25× dNTP Mix (100 mM) 0.8 
Reverse Transcriptase (50 U/µl) 0.8 
1 µg RNA diluted with dH2O 14.4 
Table 19: Reverse transcription protocol for EwS cells. 
 
The qRT-PCR reactions were performed using ‘SYBR green master mix’ that was mixed with diluted 
cDNA (1:10) and 10 µM forward/ reverse primer mix (Table 20) on a Bio-Rad CFX Connect instrument 
and analyzed using Bio Rad CFX Manager 3.1 software.  
 
Components Amount (µl) 
SYBR green master mix 7.4  
10 µM FW/RV primer mix 0.9 
cDNA (1:10 diluted in dH2O) 6.7 
Table 20: qRT-PCR protocol with SYBR green master mix. 
 
Gene expression values were calculated using the “2^−(ΔΔCt) method” (Livak and Schmittgen, 2001) 
relative to the housekeeping gene RPLP0 as internal control. Thereby ∆CT values of “RPLP0-Target” 
were calculated and the ∆∆CT value of each sample was calculated relative to the internal control 
(Sample X – control) and log2-transformed. Primers were purchased from MWG Eurofins Genomics 
and listed in the section 3.1.12.3. 
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The thermal conditions for qRT-PCR were as follows (Table 21): 
Step °C Time Cycles 
Heat activation 95 2 min 1 
Denaturation 95 10 sec 
50 Annealing 60 20 sec 
Extension 60 20 sec 
Final denaturation 95 30 sec 1 
Table 21: Thermal cycling conditions for qRT-PCR. 
 
3.2.3.2 DNA extraction 
For genomic DNA extraction, about 1 × 107 cells were collected and genomic DNA was extracted with 
the NucleoSpin Tissue/DNA kit according to manufacturer’s protocol. DNA concentration was 
measured by Nanodrop. 
 
3.2.4 Biochemistry 
3.2.4.1 Generation of cell lysates and Bradford assay  
RDES_shCtrl, RDES_shSOX6_2, RDES_shSOX6_3, TC-32_shCtrl, TC-32_shSOX6_2 and TC-32_shSOX6_3 
EwS cell lines were treated for 96h with Dox to induce SOX6 knockdown. To this end, 2 × 105 cells were 
seeded out and after 96h whole cellular proteins were extracted with 100 µl/ 6-well RIPA buffer 
containing 1 mM Na3VO4 and 100 µl/ml protease inhibitor cocktail.  
The total protein concentration of cell lysates was determined by Bradford protein assay (Bradford, 
1976). The standard curve was determined by diluting Bovine Serum Albumin Standard (0.125 µg, 0.25 
µg, 0.5 µg, 0.75 µg, 1 µg and 2 µg) and the Bradford reagent 1:5 with dH2O. The standard curve was 
measured and later used for calculation of the relative protein concentrations of the samples. The 
protein concentration was determined by diluting 1 μl of cell lysate in 99 μl of diluted (1:5) Bradford 
reagent. The protein absorption was measured at 595 nm with the spectrophotometer.  
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3.2.4.2 SDS-PAGE and Western Blot 
For Western blot analyses the lysates were mixed in 4× loading dye containing DDT and denatured at 
95°C for 5 min. Lysates were stored at –80 °C. The separation of proteins was done by SDS-
polyacrylamide-gelelectrophoresis (SDS-PAGE). Therefore, the stacking and the running gel were 
prepared according to section 3.1.11.  
The nitrocellulose membranes were incubated with a primary mouse monoclonal anti-SOX6 antibody 
(1:1000) diluted in 5% BSA-TBST, and mouse monoclonal anti-GAPDH (1:800) and rabbit monoclonal 
anti-TXNIP (1:1000) diluted in 5%-milk-TBST. The nitrocellulose membranes were secondarily 
incubated with anti-mouse IgG (H+L) HRP-coupled (1:3000) or anti-rabbit IgG-HRP (1:5000) in 5%-milk-
TBST. Proteins were detected using chemiluminescence HRP substrate and a densitrometric protein 
quantification was carried out by ImageJ. 
 
3.2.5 Cell-based assays 
3.2.5.1 Cell proliferation 
For proliferation assays with sipool-mediated knockdown of SOX6 and cell-cycle related genes (CDCA3, 
DEPDC1 and E2F8) reverse transfection with Lipofectamine RNAiMAX was performed according to 
siTOOL’s protocol. All sipools consist of 30 different short interfering RNAs (siRNAs) directed against 
the target transcript, which largely eliminate off-target effects (Hannus et al., 2014).  
For this purpose, 7.5 × 104 cells/12-well for RDES, TC-32 and POE were seeded out in serum-free 
medium on the same day as the transfection with a sipool specifically directed against SOX6, CDCA3, 
DEPDC1 and E2F8 (Table 22) or a corresponding non-targeting sipool Control (sipControl) at a final 
concentration of 5 – 15 nM, respectively. 
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sipool Pre-dilution stock Final concentration 
CDCA3 0.25 µM 5 nM 
DEPDC1 0.5 µM 10 nM 
SOX6 0.5 µM 10 nM 
E2F8 0.75 µM 15 nM 
Table 22: Pre-dilutions and final concentration of sipool-mediated transfection. 
 
OptiMEM for sipool as well as sipool pre-dilution stocks (1) and OptiMEM for RNAiMax as well as 
RNAiMax (2) were mixed simultaneously. Subsequently, both mixes ((1) + (2)) were mixed, vortexed in 
a 1:1 ratio (3) and incubated for 5 min at RT. Thereafter, 250 µl of this transfection-mix (3) was given 
to 750 µl of cell suspension (4) in a 12-well and mixed well (Table 23): 
 
Final 
volume/ 
well 
OptiMEM 
for sipool 
dilution 
Sipool 
pre-
dilution 
OptiMEM 
for 
RNAiMax 
RNAiMax 
Transfection 
mix/well 
Cell seeding 
density 
(cells/ml) 
Cell 
suspension 
volume 
 (1) (2) (3) (4) 
1 ml 105 µl 20 µl 123 µl 2 µl 250 µl 75.000 750 µl 
Table 23: Transfection protocol for sipool-mediated knockdown. 
 
For proliferation assays with siRNA-mediated knockdown of TXNIP, reverse transfection with 
Lipofectamine RNAiMAX was performed. To this end, 2.5 × 105 cells/6-well were seeded out in serum-
free medium the same day as the transfection with a siRNA specifically directed against TXNIP or a 
corresponding non-targeting siRNA (siCtrl), at a concentration of 25 nM, respectively. The transfection 
was performed according to the manufacturer’s protocol with a final concentration of 10 nM. 
For proliferation assays with shRNA-mediated SOX6 knockdown, 2 × 105 EwS cells were seeded in a 
6-well plate and treated with 0.1 µg/ml Dox every 48h for transient knockdown for a total period of 
96h.  
The knockdown efficacy of all knockdown-variants, was validated by qRT-PCR and/or Western blot. 
48h after transfection cells were re-transfected or Dox was re-freshed. The cell viability was 
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determined 96h after the initial transfection, including the supernatant, by counting the cells with 
Trypan-Blue using standardized hemocytometers. 
 
3.2.5.2 Clonogenic (2D) and sphere (3D) assay 
For clonogenic growth assays, EwS cell lines, harboring a shRNA against SOX6 or Ctrl, were seeded at 
low density (200 cells) in a 12-well plate and grown for 21 days. Thereby Dox was renewed every 48h 
to maintain SOX6 knockdown. Three technical replicates per biological replicate were counted 
independently and the colony area was measured with the ImageJ Plugin Colony area. The 
clonogenicity index was calculated by multiplying the counted colonies with the corresponding colony 
area. 
For the sphere formation assay (anchorage-independent growth), EwS cell lines, harboring a shRNA 
against SOX6, were pre-treated with Dox 48h before seeding to induce the knockdown of SOX6. 
Consequently, 1 × 103 cells/96-well were seeded in 200 µl total volume in ultra-low attachment plates 
for 12 days. Assays with A673 EwS cell lines with siRNA against SOX6 were performed as described in 
section 3.2.5.1. Thereby, the transfection was repeated every 48h. Subsequently, low attachment 
wells were photographed and only spheres larger than 500 µm in diameter were counted. The area 
was measured using ImageJ and the sphere volumes were calculated as follows: V = 4/3×π×r3. The 
sphere index was calculated by multiplying the counted colonies with the corresponding colony 
volume. 
 
3.2.5.3 Cell cycle analysis with propidium iodide 
For cell cycle analysis, EwS cell lines harboring a shRNA against SOX6, were seeded at 4 × 105 cells per 
10 cm dish and subsequently starved for 56h. Stimulation of the cells occurred with 10% FCS for 20h. 
On the day of analysis, the cells were fixed with ice-cold 70% ethanol, treated with 100 µg/ml RNAse 
and stained with 50 µg/ml propidium iodide (PI) for 45 min in the dark. The analysis of the cell cycle 
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was performed within 2 – 3 hours in time with BD Accuri C6 Cytometer by counting at least 1 × 105 
events. An example for the gating strategy is provided in Figure 5.  
 
 
Figure 5: Gating strategy for cell cycle analysis with propidium iodide. 
 
3.2.5.4 Determination of apoptosis with Annexin V staining 
For determination of apoptosis with Annexin V staining, EwS cell lines harboring a shRNA against SOX6 
were seeded at 3 × 105 cells per 10 cm dish and treated with 0.1 µg/ml Dox every 48h to ensure SOX6 
knockdown. After 96h, cells were washed with PBS and the cells were re-suspended in 500 µl 1x 
Annexin V buffer containing 5 µl of Annexin V and 5 µl PI solution for 15 min. Analysis of Annexin V 
positivity was performed within 1h with BD Accuri C6 Cytometer by counting at least 1 × 105 events. 
An example for the gating strategy is provided in Figure 6. 
 
Figure 6: Gating strategy for apoptosis analysis with Annexin V staining. 
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3.2.5.5 Drug-response assay  
For drug-response assays with Elesclomol and Menadione, 1.5 × 103 cells of RDES and TC-32 with Dox-
inducible SOX6 knockdown as well as 2.5 x 103 cells of MSC-52 and SAOS-2 were seeded in 96-well 
plates. Therefore, EwS cell lines harboring shRNA against SOX6 were pre-treated for 48h with Dox to 
induce SOX6 knockdown whereas MSC-52 and SAOS-2 cells were not pre-treated before the addition 
of Elesclomol (STA-4783) and Menadione. The pre-treatment medium was discarded prior to the 
addition of different concentrations of Elesclomol or Menadione ranging from 0.1 nM to 10 µM or 0.1 
µM – 25 µM, respectively with/without Dox to the cells in a total volume of 100 µl per technical 
replicate for a further 72h.  
In order to measure drug-response in siRNA-mediated TXNIP knockdown cells with Elesclomol, 3.5 × 
103 TC-32 cells were seeded in a 96-well plate for 48h and subsequently pre-treated with siRNA against 
TXNIP (final concentration 10 nM). After 48h, the 96-well plate was again transfected with siRNA 
against TXNIP but simultaneously also treated with different concentrations of Elesclomol, ranging 
from 0.1 nM to 10 µM for further 72h. 
For oxidative stress scavenging experiments with N-acetylcysteine (Nac) and Tiron, EwS cell lines, 
harboring a shRNA construct against SOX6, were additionally treated with 0.01 mM Nac or 0.1 mM 
Tiron, respectively for 72h. 
For TXNIP-rescue experiments in Dox-inducible shRNA-mediated SOX6 knockdown cells by a 
cumate-inducible TXNIP re-expression, TC-32 EwS cells were pre-treated with 0.1 µg/ml Dox and 
5 µg/ml cumate for 48h to induce SOX6 knockdown and simultaneously re-induce TXNIP expression in 
these cells to physiological levels. Subsequently, the cells were also treated with 0.1 nM to 10 µM 
Elesclomol with/without Dox and cumate, respectively for further 72h. 
For rescue experiments with H2O2, 1.5 × 103 the EwS cells were seeded in 96-well plates and 
pre-treated for 48h with Dox to induce SOX6 knockdown. After 48h, the cells were either further 
subjected to Elesclomol (10 nM) or vehicle (DMSO) and additionally treated with 30 mM H2O2.  
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After 72h, Resazurin (16 µg/ml) was added to the cells in order to measure cell viability. The relative 
IC50 concentrations were calculated using PRISM 5 and normalized to the respective controls. 
 
3.2.5.6 Detection of oxidative stress by DCF-DA fluorescence 
For detection of oxidative stress changes, EwS cells were seeded at a density of 5 × 104 cells/2 ml per 
6-well and either 1) directly treated for 96h with Dox to induce the knockdown, 2) directly treated for 
48h with 0.01 mM Nac or 0.1 mM Tiron or 3) treated for 24h with 10 nM Elesclomol. For detection of 
oxidative stress changes after TXNIP knockdown, TC-32 cells were seeded at a density of 7 × 
104 cells/2 ml per 6-well and reversely transfected with siRNA against TXNIP.  
After 96h, 2.5 µM 2′,7′-dichlorodihydrofluorescein diacetate (DCF-DA) was added to the medium 
containing the cells for 30 min at 37°C. Subsequently, the cells were harvested and re-suspended in 
PBS and further incubated for 40 min, in the dark to recover. Flow cytometry analysis with Accuri C6 
Cytometer was carried out by measuring at least 1 × 105 events. This gating strategy is provided in 
Figure 7. 
 
Figure 7: Gating strategy for oxidative stress analysis with DCF-DA staining. 
 
 
3.2.5.7 Detection of mitochondrial ROS (mito-ROS) by MitoSOX Red fluorescence 
For the detection of specific mitochondrial reactive oxygen species, so-called mito-ROS, cells were 
incubated after Elesclomol treatment with MitoSOX Red, which can detect mitochondrial superoxide 
anions. The resulting MitoSOX Red fluorescence signal was normalized to the mitochondrial mass 
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determined by the MitoTracker Green fluorescent signal (De Biasi et al., 2016; Ikeda et al., 2019). To 
this end, 1.5 × 105 cells/6-well were seeded in an appropriate amount of medium and directly treated 
for 96h with Dox to induce SOX6 knockdown or directly treated for 24h with 10 nM Elesclomol, or 24h 
with 0.1 mM Tiron. The cells were first incubated with 200 nM MitoTracker Green within the 6-well in 
PBS for 30 min and subsequently simultaneously incubated with 5 µM MitoSOX Red for further 15 min. 
The cells were washed twice with PBS, trypsinized and re-suspended in PBS for flow cytometry analysis 
with BD Accuri C6 Cytometer thereby measuring at least 1 × 105 events. MitoTracker Green was used 
as mitochondrial mass for internal control. This gating strategy is explained in Figure 8. 
 
 
Figure 8: Gating strategy for mito-ROS by MitoSOX Red and MitoTracker Green staining. 
 
 
3.2.5.8 Luciferase assay 
The enhancer activity of the microsatellite was measured through the cloning of the GGAA-mSat into 
the pGL3-Promotor vector. The forward transfection was performed with the Lipofectamine LTX with 
Plus Reagent. To this end, 3 × 105 A673/TR/shEF1 cells for each 6-well were seeded out one day before. 
A673/TR/shEF1 cells were simultaneously and transiently transfected with control plasmid (pRL 
Renilla) and pGL3_mSat_alleleA or pGL3_mSat_alleleB respectively or pGL3_empty (Table 24). For 
verification of the transfection procedure and also for the quantification of the knockdown efficacy of 
shRNA-mediated EWSR1-FLI1 knockdown in Dox-inducible A673 EwS cells, those cells were 
additionally transfected with a pCAG-YFP vector for knockdown efficiency. 
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 Number of well Amount 
(1) Amount of DNA* 1 µg 
(2) OptiMEM + 10 ng pRL Renilla 200 µl 
(3) Plus reagent   
(4) Incubate for 10 min at RT 
(5) Lipofectamine LTX 2.5 µl 
(6) Incubate for 25 min at RT 
(7) Add on each well 191 µl 
(8) Medium in well 1.8 ml 
Table 24: Transient transfection protocol of pGL3-mSat* or pCAG-YFP* in A673/TR/shEF1 cells for 
luciferase assay. 
 
On the second day of seeding 2 µg of pGL3_empty, pGL3-mSat_alleleA, pGL3-mSat_alleleB or pCAG-
YFP vector (1) were mixed with OptiMEM containing 10 ng pRL Renilla plasmid (2) per 6-well as a house 
keeping control. The Plus reagent (3) was gently mixed with diluted DNA and incubated for 10 min at 
RT (4). The Lipofectamine LTX was added directly to the diluted DNA and incubated further 25 min at 
RT (6). An appropriate amount (7) of diluted DNA mixture was added to the serum-containing medium 
of the cells (8). The medium was changed 4h later and replaced by Dox-containing RPMI medium to 
induce EWSR1-FLI1 knockdown in A673 cells (Table 24). After 48h, transfection efficacy was evaluated 
by fluorescence microscopy of pCAG-YFP-transfected cells. Subsequently, cell lysates were extracted 
and measured with Beetle and Renilla juice according to manufacturer’s protocol using a Luminometer 
device. The EWSR1-FLI1 knockdown efficacy was measured by extracting the RNA out of the 
YFP-transfected cells and subsequently performing qRT-PCR analysis with EWSR1-FLI1 primers. 
 
3.2.6 Histology 
3.2.6.1 Immunohistochemistry of cleaved caspase 3, SOX6, Ki67, 8-OHG and TXNIP 
Mice xenografts were cut in 4-μm sections for immunohistochemistry and antigen retrieval was carried 
out by heat treatment with Target Retrieval Solution Citrate pH6 for SOX6, cleaved caspase 3, Ki67 or 
with Epitope Retrieval Solution pH6 for TXNIP. Subsequently, the slides were stained with either 
polyclonal anti-SOX6 antibody raised in rabbit (1:1600) or with monoclonal anti-Ki67 raised in rabbit 
(1:200) for 60 min at RT, followed by a monoclonal secondary horseradish peroxidase (HRP)-coupled 
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horse-anti-rabbit antibody of the ImmPRESS Reagent Kit. Thereby, AEC-Plus was used as chromogen 
and slides were counterstained with Hematoxylin Gill`s Formula.  
For 8-OHG staining, the slides were pre-treated with proteinase K for 15 min at 37°C. The slides were 
incubated with the polyclonal cleaved caspase 3 primary rabbit antibody (1:100) or with a polyclonal 
anti-TXNIP rabbit antibody (1:250) or a monoclonal anti-8-OHG antibody raised in mouse (1:2500) for 
60 min at RT followed by a monoclonal secondary horseradish peroxidase (HRP)-coupled horse-anti-
rabbit or horse-anti-mouse antibody of the ImmPRESS Reagent Kit. Thereby, DAB+ was used as 
chromogen and Hematoxylin Gill`s Formula for counterstaining. All the stainings were performed by 
Andrea Sendelhofert and Anja Heier.  
 
3.2.6.2 Quantification of immunohistological stainings 
An evaluation of the immunoreactivity of SOX6, TXNIP and 8-OHG was carried out in analogy to the 
scoring of the hormone receptor Immune Reactive Score (IRS) from Remmele and Stegner (Remmele 
and Stegner, 1987) ranging from 0 – 12 as previously described (Baldauf et al., 2018a). The percentage 
of positive cells was scored and classified in five grades (grade 0 = 0 – 19%, grade 1 = 20 – 39%, grade 
2 = 40 – 59%, grade 3 = 60 – 79% and grade 4 = 80 – 100%). In addition, the intensity of the marker 
immunoreactivity was determined (grade 0 = none, grade 1 = low, grade 2 = moderate and grade 3 = 
strong). The final IRS was calculated by multiplying the grade by the intensity.  
To evaluate the immunohistological staining of cleaved caspase 3 and Ki67, six high power field (HPF) 
of 20× magnification pictures were analyzed through an estimation of the stained areas compared to 
the whole area. 
For a quantification of necrosis, the slides were stained with H&E and the necrotic area was compared 
to normal tissues by four different observers. For mitoses quantification, six HPF areas of H&E-stained 
slides with 20× magnification were count by three different observers. 
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The quantifications was carried out by Dr. Fabienne Wehweck, Dr. Thomas Grünewald Ph.D., 
Maximilian Knott and Jing Li. 
 
3.2.6.3 Human samples and ethics approval 
Human tissue samples were retrieved from the archives of the Institute of Pathology of the Ludwig-
Maximilians University (LMU) Munich (Germany) following approval by the institutional review board. 
The current study (approval no. 550-16 UE) was approved by the ethics committee of the LMU Munich. 
 
3.2.7 Survival analysis 
To test for association of SOX6 protein expression with EwS patients’ survival, a validation-cohort 
comprising tumor specimens of 161 EwS patients with clinical annotations, treated with first-line 
therapy, were analyzed. Tumor specimens were immunohistochemically stained for SOX6 (see 3.2.6.1) 
and staining intensity was quantified according to the immunoreactivity score (IRS). Patients were 
stratified by different IRS values in those with lower and higher SOX6 expression. Differences in overall 
survival (OS) between the resulting patients groups was assessed by the Kaplan-Meier method (Log-
rank Mantel-Cox test).  
 
3.2.8 In vivo models 
3.2.8.1 Xenograft subcutaneous murine model 
For long-term in vivo analysis of SOX6 functionality, 3 × 106 EwS cells harboring a shRNA against SOX6 
were injected with Geltrex Basement Membrane Mix 1:1 in the right flank of 10 to 12 weeks old 
NOD/Scid/gamma (NSG) mice. Tumor volume was measured and monitored every second day with a 
caliper and calculated with the standard formula (L × l2) / 2. The mice were separated into two groups 
at the moment when the tumor reached an average volume of 80 mm3. For the analysis of the tumor 
growth one group of mice was treated with 2 mg/ml BelaDox dissolved in drinking water containing 
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5% sucrose to induce an in vivo knockdown, whereas the control group of mice only received 5% 
sucrose. Once the tumors of the control group of mice reached an average volume of 1,500 mm3, all 
the mice of the same experiment were sacrificed by cervical dislocation.  
 
3.2.8.2 Intravenous injection of Elesclomol 
For the in vivo drug assay with Elesclomol, 3 × 106 EwS cells were subcutaneously injected with Geltrex 
basement Membrane Mix in mice as described above. Whenever the tumors reached an average 
volume of 80 mm3, the mice were randomly separated into two groups and subsequently either 
treated intravenously (i.v.) with 5 mg/kg Elesclomol, or vehicle (DMSO) for 5 days/week, for the 
subsequent 2.5 weeks. 
Once the tumors of the control group of mice (vehicle) reached an average volume of 1,500 mm3 or 
the experimental end-point was reached, all the mice were sacrificed by cervical dislocation. Thereby, 
tumors were extracted and a small sample was snap frozen in liquid nitrogen for RNA extraction. The 
remaining tumor tissue was fixed in 4%-formalin and paraffin-embedded for further 
immunohistological analysis.  
Animal experiments were approved by local authorities and conducted in accordance with the 
recommendations of the European Community (86/609/EEC) and UKCCCR (guidelines for the welfare 
and use of animals in cancer research). The sample size was not predetermined. The above mentioned 
experiments were performed by Dr. med. vet. Shunya Ohmura. 
 
3.2.8.3 Orthotopic bone injection model 
As EwS is a bone-related disease, analysis of tumor growth in bone was performed. Orthotopic bone 
injection models have already been described for EwS (Hauer et al., 2013; Stewart et al., 2014, 2017). 
For orthotopic mouse experiments, mice were first analgo-anesthetized by intra-peritoneal injection 
(i.p.) of 0.5 mg/kg Medetomidin, 5 mg/kg Midazolam and 0.05 mg/kg Fentanyl (per body weight). Only 
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when mice did not show any reflexes, the joint was disinfected with iodide tincture before 
pre-puncturing the tibia with a 26 Gauge needle. Subsequently, using a 28 Gauge needle, 2 × 105/20 µl 
of EwS cells harboring a shRNA against SOX6 were injected intraosseously in the right tibia of 10 to 12 
week old NOD/Scid/gamma (NSG) mice. To prevent bleeding at the injection side, a pad was tightly 
pressed against the puncture. For durable pain prophylaxis, mice were treated with 0.05 mg/kg 
Buprenorphin i.p. and analgo-anesthetics were antagonized with 1.2 mg/kg Naloxon and 2.5 mg/kg 
Atipamezol subcutaneously. The mice were tightly monitored until they had fully recovered from 
anesthesia. The following day, mice were randomized into two groups and either treated with 2 mg/ml 
BelaDox dissolved in drinking water containing 5% sucrose to induce an in vivo knockdown, or only 
received 5% sucrose for the control group. Osseous tumor growth was monitored every two days. 
Once the tumor growth provoked an obvious limping in individuals, they were sacrificed by cervical 
dislocation. These experiments were performed by Florencia Cidre Aranaz, PhD and Dr. med. vet. 
Shunya Ohmura. 
 
3.2.8.4 Patient-derived xenograft (PDX) model  
For the establishment of xenografts, EwS tumor tissue was surgically removed from EwS patients and 
small pieces (3 to 4 mm in width) were subcutaneously transplanted into immunodeficient NOD/SCID 
mice. The gender of the mice was chosen accordingly to the gender of the patient. The PDX tumor 
diameters were measured every second day with a caliper and the PDX tumor volume were calculated 
by the formula L×l2/2. When the PDXs had reached an average volume of 1.5 cm3 (defined end-point), 
the mice were sacrificed by cervical dislocation. Thereby, the PDX tumors were extracted, fixed in 
4%-formalin and subsequently paraffin-embedded for immunohistology as described above (see 
3.2.6.1). 
All animal experiments were conducted in collaboration with Experimental Pharmacology and 
Oncology GmbH, Berlin Buch in accordance with the UKCCCR for the welfare and use of animals in 
cancer research, German Animal Protection Law and had been approved by local authorities (LaGeSo, 
Berlin, Germany). 
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3.2.9 Bioinformatic data analyses 
3.2.9.1 Analysis of published DNase sequencing (DNase-Seq) and chromatin immuno-precipitation 
DNA sequencing (ChIP-Seq) data 
ENCODE SK-N-MC DNase-Seq (GSM736570) and ChIP-Seq data (GSE61944) were downloaded from the 
Gene Expression Omnibus (GEO) and processed as previously described (Grünewald et al., 2015). The 
following samples were loaded into the UCSC genome browser:  
ENCODE_SKNMC_hg19_DNAseHS_rep1 
GSM1517546_SKNMC.shGFP96.FLI1 
GSM1517555_SKNMC.shFLI196.FLI1 
GSM1517547_SKNMC.shGFP96.H3K27ac  
GSM1517556_SKNMC.shFLI196.H3K27ac  
GSM1517569_A673.shGFP48.FLI1 
GSM1517572_A673.shFLI148.FLI1 
GSM1517570_A673.shGFP48.H3K27ac 
GSM1517573_A673.shFLI148.H3K27ac 
 
3.2.9.2 Analysis of SOX6 expression levels in human embryoid bodies 
Publicly available gene expression microarray data of ectopically expressed EWSR1-FLI1 in human 
embryoid bodies (generated on the Affymetrix HG-U133Plus2.0 array (GSE64686) (Gordon et al., 
2016)), were normalized by Robust Multiarray Average (RMA) (Irizarry et al., 2003) using custom 
brainarray chip description files (CDF; ENTREZG, v19) yielding one optimized probe-set per gene (Dai 
et al., 2005). 
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3.2.9.3 Analysis of copy-number-variation and promoter methylation in primary EwS 
For the analysis of possible copy-number-variations (CNV), publicly available DNA copy number data 
for EwS tumors (Tirode et al., 2014) with corresponding RNA expression data (GSE34620 and 
GSE37371, n = 32) , were downloaded from the ‘soft tissue cancer – Ewing sarcoma – FR’ project from 
the International Cancer Genome Consortium (ICGC) Data Portal and from GEO of the NCBI, 
respectively. For the analysis of the SOX6 locus, segment mean values were extracted from these data 
using Visual Basic for Applications (VBA). The log2-transformed expression of the SOX6 gene was 
correlated with the aforementioned and generated segment mean.  
For the analysis of CpG methylation, publicly available data on CpG methylation in 40 EwS tumors 
(GSE88826) (Sheffield et al., 2017) and the corresponding RNA expression data (GSE34620) were 
downloaded from GEO. For the analysis of the SOX6 locus, the ratio of methylated versus 
unmethylated reads was calculated for two CpG sites (CpG1 hg19: chr11:15994482; CpG2 hg19: 
chr11:15994519) in each sample (n = 40) using VBA, covering at least four reads. The bioinformatic 
analyses were performed by Dr. med. Martin Orth. 
 
3.2.9.4 Transcriptome and splicing analyses 
Microarray analyses were performed in order to assess the impact of SOX6 on gene expression and 
alternative splicing in EwS. Herefore, 1.2 × 104 cells were seeded in 6-well plates and treated with Dox 
(refreshing Dox every 48h) for 96h. Total RNA was extracted with the ReliaPrep miRNA Cell and Tissue 
Miniprep System and the transcriptome analysis was profiled at IMGM laboratories. The RNA quality 
was measured with a Bioanalyzer and samples with RNA integrity numbers (RIN) > 9 were hybridized 
to Human Affymetrix Clariom D microarrays. The generated data were quantile normalized with 
Transcriptome Analysis Console (V4.0) using the SST-RMA algorithm as previously described (Machiela 
et al., 2018). The annotation of the data, on gene and exon level, was performed using the Affymetrix 
library for Clariom D Array (version 2, human). Differentially expressed genes (DEGs) with consistent 
and significant fold changes (FCs) across shRNAs and cell lines were identified as follows:  
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First, data were log2 transformed and subsequently minimally expressed genes were excluded. This 
step was crucial to avoid false discovery artifacts due to minimally expressed genes. Therefore, the 
expression of ERG (mean log2 expression signal of 6.05) was declared as minimal cut-off as this gene 
is not expressed in EWSR1-FLI1 positive EwS cell lines (Crompton et al., 2014). Accordingly, only genes 
with mean log2 expression signal of at least 7 were considered for further analysis.The FCs of the 
shControl samples (Dox −/+) and both specific shRNAs (Dox −/+) were calculated for each cell line 
separately. In order to clean the FC from the shControl, the FCs observed in the respective shControl 
samples were subtracted from those seen in both shSOX6 samples and resulted in the final FCs for 
each specific shRNAs in each cell line. These final FCs for both specific shRNAs were averaged across 
cell lines to obtain the final mean-FC per gene across shRNAs and cell lines. As the FC for SOX6 was –
1.486, only those genes that had a minimum absolute log2 FC of 1 were considered strongly regulated 
and thus, DEGs.  
Additionally, the false discovery rate (FDR) was estimated for each gene using the R package ‘qvalue’ 
from Bioconductor (Storey et al., 2019). To identify enriched gene sets, a GSEA was carried out with all 
genes that comply with the minimum expression criteria of log2 FC of 1. In this regard, the genes were 
ranked by their expression FC between the groups Dox (−/+), and a pre-ranked GSEA (MSigDB v5.2, 
c2.cpg.all) with 1,000 permutations was performed (Subramanian et al., 2005).  
To assess the potential role of SOX6 on alternative splicing, probe selection region (PSR) expression on 
Affymetrix microarray was analyzed more closely. In case the RNA was not alternatively spliced, the 
ratio of each probe selection region (PSR) expression with and without SOX6 knockdown remains 
unaltered irrespective of up- or downregulation of the SOX6 gene. The additional FC between the 
expression value of each PSR before and after SOX6 knockdown to the expected FC, was calculated by 
expression regulation assessed on the gene level. Out of 539,385 PSRs with 47,851 matched genes in 
this analysis, 22,155 PSRs (10,754 genes) showed a consistently positive or negative additional log2 
transformed expression FC of ≥ 0.3. For 20,050 PSRs, thus 10,179 genes, the expression differences 
were significant (P < 0.05) when corrected for the FC on gene level.  
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However, after Bonferroni correction for multiple testing none of the PSRs remained significant. The 
generated gene expression data were deposited at the GEO (accession code GSE120576). The 
normalization of the data was done by Julia S. Gerke and the bioinformatical data analysis was 
performed by Dr. med. Martin Orth. 
 
3.2.9.5 Gene expression and drug response correlation 
Publicly available EwS cell line gene expression microarray data and matched drug-response values 
were obtained from the EBI (E-MTAB-3610) and from www.cancerrxgene.org (Iorio et al., 2016) in 
order to identify drugs whose efficacy correlates with SOX6 expression in EwS cells. All CEL-files 
generated on Affymetrix Human Genome U219 arrays were simultaneously normalized using RMA 
(Irizarry et al., 2003) and a custom brainarray chip description file (v20, ENTREZG) yielding one 
optimized probe set for each gene (Dai et al., 2005). The Pearson correlation coefficient (rPearson) for all 
tested drugs in EwS cell lines and its significance between SOX6 expression and the IC50 values were 
calculated.  
 
3.2.10 Statistical analysis 
Statistical data analysis was performed using PRISM 5 (GraphPad Software Inc.) on the raw data. 
Comparison of two groups in functional in vitro experiments was carried out using a two-sided Mann-
Whitney test if not otherwise specified. Data are displayed as dot plots with horizontal bars 
representing means and whiskers representing the standard error of the mean (SEM). Sample size for 
all in vitro experiments were chosen empirically. 
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4. Results 
EwS predominantly occurs in bone or soft tissues and displays a highly proliferative, undifferentiated 
and embryonal phenotype. The transcription factor SOX6 is mainly involved in the cell cycle regulation 
during endochondral ossification, where it regulates chondrocyte proliferation. As EwS cells seems to 
arise from osteo-/chondrogenic progenitors, a closer insight into the expression of the bone-
associated transcription factor SOX6 in EwS appeared promising.  
 
4.1 SOX6 is highly expressed in EwS compared to other sarcomas 
In order to validate the hypothesis-driven assumption of SOX6 being part of the typical 
undifferentiated but highly proliferative phenotype of EwS, an expression pattern of SOX6, from a 
previously established DNA microarray set (> 750) (Baldauf et al., 2018a, 2018b) comprising 18 
representative normal tissues types and 10 cancer entities, was analyzed. Indeed, comparative 
analyses revealed a SOX6 overexpression in EwS in contrast to other cancers and normal tissue (Figure 
9A, B). The depicted mRNA expression levels (Figure 9A) were also validated at the protein level (Figure 
9B) in the same comprehensive tissue microarray (Baldauf et al., 2018a, 2018b). Both analyses showed 
that SOX6 is highly expressed in EwS tumors, but with inter-tumor heterogeneity (Figure 9 A, B, C). 
Results 
 
59 
 
 
Figure 9: SOX6 is highly but variably expressed in EwS  
A) Analysis of SOX6 expression at the mRNA level in EwS tumors, sarcomas/pediatric tumors compared 
to normal tissue types. The number of samples is indicated in parentheses. Data represent medians. 
B) Validation of SOX6 expression at the protein level by IHC in EwS tumors and other 
sarcomas/pediatric tumors compared to normal tissue types. Data represent median IRS. The number 
of samples is given in parentheses. C) Representative pictures of SOX6 staining by IHC of EwS tumors, 
sarcomas and normal tissues from (B). Scale bar = 20 µm. ASPS = alveolar soft part sarcoma; GIST = 
gastrointestinal stromal tumor. 
 
The higher, yet heterogeneous mRNA expression of SOX6 was also observed in 27 EwS cell lines 
compared to cell lines of three other pediatric cancer types including osteosarcoma (U2OS and 
SAOS-2), neuroblastoma (TGW and SK-N-AS) and rhabdomyosarcoma (Rh36 and Rh4) (Figure 10). 
Based on this SOX6 expression pattern TC-32, RDES and POE cell lines were selected to perform in vitro 
and in vivo experiments in this thesis. 
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Figure 10: SOX6 is heterogeneously expressed in EwS cell lines 
Analysis of relative SOX6 mRNA levels of different EwS, rhabdomyosarcoma, neuroblastoma and 
osteosarcoma cell lines to that of TC-32 by qRT-PCR. Pink color: highest SOX6 expression (TC-32, RDES 
and POE), blue color: intermediate SOX6 expression (ORS, EW17 and SK-N-MC), green color: low SOX6 
expression (A673, EW7). Means and SEM, n ≥ 3. **P < 0.01, *P < 0.05. 
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4.2 SOX6 does not correlate with EwS patient survival 
To investigate if SOX6 expression correlates with patients’ overall survival (OS) in EwS, a validation 
cohort comprising 161 EwS tumor specimens, for which matched clinical data were available, was 
performed. 
Stratifying SOX6 protein by different cut-offs such as no (IRS = 0), intermediae (IRS = 1 – 4) or high (IRS 
≥ 4) SOX6 expression revealed that survival is independent of SOX6 (P value = 0.667) (Figure 11). 
P values were corrected for multiple testing by Bonferroni correction. 
 
Figure 11: Kaplan-Maier curves comprising 161 primary tumors of EwS patients. 
Depicted are data of primary tumors of EwS patients categorized in no SOX6 expression (green), 
intermediate SOX6 expression (pink) and high SOX6 expression (blue); P value = 0.669. High SOX6 
expression is referred to IRS ≥ 4. 
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4.3 Functional analysis of SOX6 in vitro and in vivo 
In the following part of this thesis, the functional role of SOX6 in vitro and in vivo regarding proliferation 
and tumorigenesis was investigated more closely. As described in the methods part, EwS cell lines 
harboring a Dox-inducible shRNA against SOX6 were generated for long-term analysis.  
 
4.3.1 SOX6 is induced by EWSR1-FLI1 via an intronic enhancer-like GGAA-mSat 
As SOX6 was previsously shown to be highly expressed in EwS compared to other sarcomas and cancers 
(Figure 1), the assumption that can be made is that SOX6 might be regulated by the fusion protein 
EWSR1-FLI1. 
To further investigate the interaction between SOX6 and EWSR1-FLI1, the EwS cell lines A673 and 
SK-N-MC were transduced with a Dox-inducible shRNA against the fusion EWSR1-FLI1. The fusion 
oncogene knockdown reduced SOX6 expression in a time-dependent manner in vitro (Figure 12A) and 
in vivo (Figure 12B). The analysis of gene expression microarray data of human embryoid bodies upon 
ectopical expression of the EWSR1-FLI1 fusion oncogene revealed a strong SOX6 induction (Figure 
12C). 
Publicly available DNase-Seq data from SK-N-MC EwS cell lines, as well as ChIP-Seq data of EWSR1-FLI1 
from A673 and SK-N-MC EwS cell lines were investigated in order to understand the underlying 
regulatory mechanism between SOX6 and EWSR1-FLI1. Indeed, a prominent EWSR1-FLI1 ChIP-Seq 
peak mapped to a GGAA-mSat within intron 1 of the SOX6 gene that was reduced upon EWSR1-FLI1 
knockdown. Interestingly, this EWSR1-FLI1 peak overlapped with a DNase I hypersensitivity site, 
indicating open chromatin, and showed EWSR1-FLI1-dependent acetylation of H3K27, standing for 
active enhancers (Figure 12D).  
To confirm the EWSR1-FLI1-dependent enhancer activity of this GGAA-mSat, a luciferase reporter 
assay was carried out. To this end, A673/TR/shEF1 cells were transfected with the pGL3 reporter 
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plasmid that contained a 1-kb fragment of the afore-mentioned SOX6-associated GGAA-mSat from the 
human reference genome (Figure 12E). 
The author of this thesis hypothesized that the observed variability in SOX6 expression might be caused 
by differences in repeat numbers at the SOX6-associated GGAA-mSat. This hypothesis is supported by 
prior studies that already showed that the enhancer activity at EWSR1-FLI1-bound GGAA-mSats 
positively correlates with the number of consecutive GGAA-repeats (Gangwal et al., 2008; Grünewald 
et al., 2015). 
To test this, paternal and maternal alleles for this GGAA-mSat (referred to as allele A and B) from eight 
EwS cell lines with largely different SOX6 expression levels (Figure 10) were analyzed and the amount 
of their consecutive GGAA-repeats were determined by Sanger Sequencing. The corresponding 
enhancer activity was measured in a luciferase reporter assay by cloning both alleles, separately into 
a reporter vector. A positive correlation (P = 0.016) of the average SOX6 expression levels with the 
average enhancer activity across cell lines was observed. This correlation was in line with the increasing 
average amount of consecutive GGAA-repeats of both alleles (Figure 12F, see list 8.2). Furthermore, 
all parental cell lines were subjected to whole-genome sequencing, which revealed that the cloned 
flanking regions adjacent to the SOX6-associated GGAA-mSat were entirely identical in all cell lines, 
thus excluding genetic variations and additional regulatory factors nearby the microsatellite. 
Of note, the observed heterogeneous SOX6 expression levels did neither correlate with alteration in 
the SOX6 promoter methylation (Figure 12G) nor with CNV (Figure 12H) at the SOX6 locus in primary 
EwS tumors.  
 
Collectively, these results indicate a possible interaction between EWSR1-FLI1 and SOX6 in EwS. SOX6 
expression appeared to be induced by the fusion protein binding to an intronic GGAA-mSat of SOX6 
that has been shown to exhibit length-dependent enhancer activity in EwS. The SOX6 regulation 
appears to be independent of the flanking regions nearby the GGAA-mSat. 
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Figure 12: EWSR1-FLI1 induces SOX6 expression via an intronic enhancer-like GGAA-mSat.  
A) Analysis of EWSR1-FLI1 and SOX6 expression by qRT-PCR in SK-N-MC/TR/shEF1 cells at different 
time points after Dox-inducible knockdown. Means and SEM, n = 3. B) Left: Analysis of EWSR1-FLI1 and 
SOX6 mRNA expression by microarrays in xenografts from A673/TR/shEF1 cells 96h after Dox-inducible 
knockdown. Means and SEM, n = 3. P values were determined via independent one-sample t-test. 
Right: Representative IHC-stainings of the same xenografted cells in mice, for (EWSR1-)FLI1 and SOX6. 
Scale bar = 20 µm. C) Analysis of SOX6 expression by microarrays in human embryoid bodies after 
ectopic EWSR1-FLI1 expression. Means and SEM, n = 3. P values were determined via unpaired 
two-sided t-test with Welch’s correction. D) Genomic overview of the SOX6 gene and its isoforms 
displaying tracks for DNAse I hypersensitivity (HS) and ChIP-Seq data for EWSR1-FLI1 and H3K27ac in 
A673 and SK-N-MC EwS cells transduced with a shRNA against EWSR1-FLI1 (shEF1) or control shRNA 
(shGFP). E) Analysis of the relative enhancer activity of the SOX6-associated GGAA-mSat (from human 
reference genome) by luciferase reporter assays in A673/TR/shEF1 cells with and without EWSR1-FLI1 
knockdown. Means and SEM, n = 4. F) Correlation of the average enhancer activity of both alleles of 
the SOX6-associated GGAA-mSat and the average SOX6 mRNA expression levels of the eight EwS cell 
lines. TC-32 cell lines was set as reference. G) Correlation analysis of the SOX6 promoter with the 
CpG-methylation sites (CpG1 and CpG2) and the corresponding SOX6 expression levels (log2) in 
primary EwS tumors, n = 40. Lines represents linear regression of the data. H) Correlation analysis of 
CNVs (represented by the segment mean) at the SOX6 locus with the corresponding SOX6 expression 
levels (log2) in primary EwS, n = 32. Lines represents linear regression of the data. ***P < 0.001, 
**P < 0.01, *P < 0.05. 
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4.3.2 SOX6 contributes to proliferation, cell-cycle progression and anchorage-independent 
colony-formation in vitro 
To investigate the function of SOX6 in EwS, three cell lines (POE, RDES and TC-32) with two different 
Dox-inducible shRNAs against SOX6 (shSOX6_2 and shSOX6_3) and a corresponding control with a Dox-
inducible non-targeting control shRNA (shCtrl) were generated. The addition of Dox (0.1 µg/ml) to the 
culture medium of transduced cells for 96h significantly silenced SOX6 expression at the mRNA and 
protein level (Figure 13A). 
Depending on the cellular context, SOX6 can act as a splicing and/or transcription factor (Ohe et al., 
2002, 2009). In order to get insight into the role of the versatile transcription factor SOX6 in EwS, SOX6-
silenced RDES and TC-32 EwS cell lines were examined by using Affymetrix Clariom D array that enables 
the simultaneous transcriptome-wide analysis of splicing events and differential gene expression. The 
knockdown of SOX6 for 96h revealed a small effect on splicing events as shown in list 8.3, whereas 
SOX6 as a transcription factor had a strong effect on differential gene expression (Figure 13B). Indeed, 
list 8.4 revealed that SOX6-silencing induced a corresponding up- or downregulation (absolute FC > 1; 
including minimal expression level of 7) of 54 and 499 genes respectively across both shRNAs and cell 
lines.  
The Figure 13C shows the result of a Gene Set Enrichment Analysis (GSEA) with differentially expressed 
genes (DEGs) of SOX6-silenced EwS cells (including all minimally expressed genes > 7), showing a strong 
depletion of proliferation-related gene signatures (see list 8.5). 
In order to validate the predicted role of SOX6 by GSEA in EwS cell lines, proliferation and knockdown 
experiments were performed using pooled short interfering RNAs (sipool) against SOX6 in five EwS cell 
lines (A673, EW7, POE, RDES and TC-32). The usage of sipools induced a 60–80% SOX6 knockdown 
compared to a non-targeting control sipool (sipCtrl) after 96h (Figure 13D). A sipool consists of 30 
different siRNAs and eliminates off-target effects (Hannus et al., 2014). In these knockdown 
experiments, cell viability was significantly reduced in all three SOX6-high expressing EwS cell lines 
(POE, RDES and TC-32) that were counted (including the supernatant) with a hemocytometer (Figure 
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13D). Interestingly, sipool-mediated SOX6-silencing in SOX6 low-expressing cell lines A673 and EW7 
could indeed significantly reduce SOX6 expression but the knockdown did not show an effect on the 
cell proliferation (Figure 13D). In accordance, long-term analysis of SOX6 knockdown in Dox-inducible 
TC-32 and RDES EwS cell lines revealed a significantly reduced 2D clonogenic and 3D sphere formation 
capacity compared to their corresponding controls (shCtrl or Dox (−)), whereas the SOX6-low 
expressing A673 cell line did not reduce 3D sphere formation capacity (Figure 13E, F).  
 
Figure 13: SOX6 promotes proliferation and anchorage-independent growth in vitro in EwS cells. 
A) Top: Western blot analysis 96h after Dox-induced SOX6 knockdown in RDES and TC-32 EwS cells. 
GAPDH was used as loading control. Bottom: Analysis of relative SOX6 expression by qRT-PCR in RDES 
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and TC-32 EwS cell lines harboring a shRNA against SOX6 or a non-targeting control shRNA (shCtrl) 96h 
after Dox-induced knockdown. Means and SEM, n = 3. B) Volcano plot of microarray data showing 
DEGs that are up- or downregulated after Dox-induced SOX6 knockdown compared to a non-targeting 
shCtrl, n = two EwS cell lines. C) Representative enrichment plots from GSEA of DEGs from RDES and 
TC-32 EwS cells 96h after Dox-induced SOX6 knockdown. NES: normalized enrichment score, NOM: 
nominal P value; FDR: false discovery rate. D) Analysis of relative SOX6 expression in A673, EW7, POE, 
RDES and TC-32 cells 96h after transfection with a sipool against SOX6 or a control sipool. Mean and 
SEM, n = 3. Right: Analysis of cell viability of the same cells depicted in (D). Means and SEM, n = 3. 
P values were determined via an independent one-sample t-test. E) Quantification of the clonogenicity 
index after 12 days of dox-induced SOX6 knockdown in RDES and TC-32 cells. Means and SEM, n = 3. 
Representative pictures of colony forming assays in a 12-well plate. F) Quantification of the sphere 
index after 12 days of shRNA-mediated (RDES and TC-32) or sipool-mediated (A673) SOX6 knockdown. 
Means and SEM, n = 3. Representative pictures of spheres from RDES cells with a shRNA against SOX6 
(RDES/TR/shSOX6_3). Scale bar = 1 mm. ***P < 0.001, **P < 0.01, *P < 0.05. 
 
As a reduction of cell viability was observed, flow cytometric assays with propidium iodide (PI) were 
carried out to test whether this effect was mediated via an alteration of the cell cycle or not. In this 
regard, serum-starved and thus G0-synchronized cells showed a significant delay in cell cycle 
progression 20h after growth stimulation by re-addition of serum in SOX6-silenced cells. Interestingly, 
this delayed cell cycle transition was not accompanied by an increase in apoptotic death (Figure 14A, 
B).  
As previously mentioned, SOX6 knockdown had a strong effect on the transcriptome. A GSEA of those 
DEGs from the microarray data pointed to an important role of SOX6 in proliferation of EwS cells (see 
list 8.5). Among the proliferation-associated genes (Figure 13C), three genes, CDCA3, DEPDC1 and 
E2F8, appeared as plausible candidate genes to promote the observed pro-proliferative phenotype of 
SOX6. Indeed, in a validation assay with RDES and TC-32 cells upon sipool-mediated SOX6 silencing, 
the mRNA levels of these pro-proliferative genes were downregulated (Figure 14C). These 
proliferation-associated genes were previously shown to be involved in cell cycle progression mostly 
during G1 − S phase transition, an involvement that has also been observed in SOX6-mediated 
knockdown cells (Ayad et al., 2003; Christensen et al., 2005; Feng et al., 2017; Mi et al., 2015). In 
accordance, the knockdown of each pro-proliferative gene with a specific sipools against CDCA3, E2F8 
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or DEPDC1 in RDES and TC-32 EwS cells phenocopied at least in part the observed anti-proliferative 
effect of SOX6 knockdown (Figure 14D).  
 
 
Figure 14: SOX6 promotes cell cycle progression. 
A) Quantification of flow cytometric analysis with PI of the cell cycle distribution in POE, RDES and TC-
32 EwS cells after dox-induced SOX6 knockdown. Means and SEM, n ≥ 3. B) Quantification of the 
relative Annexin V positivity of RDES and TC-32 cells 96h after SOX6-silencing. Means and SEM, n = 3. 
C) Heat-map showing relative expression levels of CDCA3, DEPDC1 and E2F8 in RDES and TC-32 cells 
96h after SOX6 withdrawal, n = 3. D) Analysis of cell viability of RDES and TC-32 cells after 
sipool-mediated knockdown of either CDCA3, DEPDC1 or E2F8 for 96h. Means and SEM, n = 3. P values 
were determined via an independent one-sample t-test. ***P < 0.001, **P < 0.01, *P < 0.05. 
 
Collectively, these results suggest an important contribution of SOX6 to cell cycle-related genes, cell-
cycle progression and proliferation as well as to clonogenic and anchorage-independent growth of EwS 
in vitro. 
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4.3.3 Knockdown of SOX6 inhibits tumorigenicity in vivo 
To assess the contribution of SOX6 to tumor growth of EwS cells in vivo, xenograft experiments were 
performed. Thereby, RDES and TC-32 cell lines, each harboring two Dox-inducible shRNAs against SOX6 
and one shCtrl were subcutaneously injected into the flanks of NSG mice. Mice that were injected with 
EwS cell lines expressing a non-targeting control shRNA (shCtrl) showed no effect of Dox-treatment. 
Contrarily, mice that harbored a shRNA-mediated SOX6 knockdown revealed a strong tumor growth 
reduction in both shRNA constructs and both cell lines compared to the control mice (Figure 15A). The 
knockdown of SOX6 in these xenograft tumors was confirmed ex vivo by qRT-PCR and by 
immunohistochemistry (IHC) (Figure 15B). Immunohistological analysis of these xenografted tumors 
showed that SOX6-silencing was associated with a significant reduction of cell proliferation that was 
indicated by numbers of mitotic cells per high-power filed (HPF) (Figure 15C) and Ki67 staining (Figure 
15D). In contrast, SOX6-mediated knockdown in xenografted tumors revealed no significant 
differences in cleaved caspase 3 staining compared  to the corresponding controls (Figure 15E), 
suggesting that the observed reduction of tumor growth was not caused by apoptotic cell death but 
rather by a cell cycle delay. 
To further corroborate the observed subcutaneous effect of SOX6 in xenograft models, a 
representative orthotopic tibial bone injection in NSG mice with TC-32 EwS cell lines harboring a shRNA 
(shSOX6_2) against SOX6, was performed. After intraosseous tibial bone injection, mice were directly 
treated with or without Dox to induce SOX6 knockdown.  
In analogy to the previously described subcutaneous model, Dox-treatment translated to a reduction 
of tumor growth and significantly improved mouse survival (P ≤ 0.0001) in an orthotopic bone model 
of EwS in mice (Figure 15F). 
Results 
 
70 
 
 
Figure 15: SOX6 contributes to tumor growth in vivo. 
A) Analysis of tumor growth of xenografted RDES and TC-32 EwS cells harboring a shRNA against SOX6 
(shSOX6_2/shSOX6_3) or a non-targeting control shRNA (shCtrl). Arrow: start of Dox-treatment. 
Means and SEM, n ≥ 3 mice per condition. B) Top: Relative SOX6 expression measured ex vivo by qRT-
PCR from RDES and TC-32 EwS cells shown in (A). Means and SEM, n ≥ 3 mice per condition. Bottom: 
Representative pictures of xenografts stained for SOX6; scale bar = 20 µm. C) Quantification of the 
relative number of mitoses per high-power field (HPF) of xenografts shown in (A). Means and SEM, n 
≥ 3. D) Top: Quantification of the relative Ki67 positive cells of xenografts shown in (A). Means and 
SEM, n ≥ 3. Bottom: Representative pictures of xenografts stained for Ki67; scale bar = 20 µm E) Top: 
Quantification of cleaved caspase 3 cells of xenografts shown in (A). Mean and SEM, n ≥ 3. Bottom: 
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Representative pictures of xenografts stained for cleaved caspase 3; scale bar = 20 µm. F) Kaplan-Meier 
analysis of event-free survival of mice orthotopically xenografted with TC-32/TR/shSOX6_2 cells 
with/without Dox-inducible SOX6 silencing. n = 8 animals per group. P values were determined via 
Mantel-Haenszel test. Representative pictures of tibial orthotopic injection with/without Dox. Scale 
bar = 1000 µm.  ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. 
 
Taken together, these results depict a contribution of SOX6 to tumor growth in xenografted mice with 
EwS cell lines. 
 
4.3.4 Correlation of tumor growth in PDX of EwS patients with SOX6 expression 
To further validate the tumorigenicity of SOX6 expression in EwS, eight patient-derived xenografts 
(PDX) were subcutaneously grown in the mice, which included high, intermediate and low SOX6 
expression. The analysis of the PDX staining revealed that high SOX6 expression (validated by IHC), was 
associated with high positive Ki67 staining resulting in a positive correlation between SOX6 expression 
and Ki67 staining (rpearson= 0.856; P ≤ 0.007). Furthermore, a negative correlation was observed 
between the tumor growth and the corresponding SOX6 expression (rpearson = –0.752, P = 0.013) (Figure 
16). 
 
 
Figure 16: Correlation of tumor growth in patient-derived EwS xenografts (PDX) with SOX6 
expression.  
Correlation of the tumor growth or Ki67 positive staining with SOX6 expression in PDX tumors, n = 8. 
Lines indicate linear regression of the data. 
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4.4 Therapeutic aspect of SOX6 
Next to its role in the development of the CNS, the developmental transcription factor SOX6 is known 
to be mostly expressed during endochondral ossification in adolescents. This fact makes SOX6 a 
suitable biomarker, as the direct targeting of a developmental factor with inhibitors would cause 
severe side effects in the bone formation and nervous system of growing children (Smits et al., 2001). 
The author aimed to explore whether high SOX6 levels in EwS may constitute a specific vulnerability 
of EwS that may be exploited therapeutically. 
 
4.4.1 SOX6 expression confers sensitivity toward small-molecule Elesclomol 
A published gene expression dataset with matched drug-response data comprising 22 EwS cell lines 
(Iorio et al., 2016) and 250 drugs was interrogated. The Pearson correlation coefficient and the 
statistical significance of the corresponding IC50 values were calculated for all tested drugs with the 
observed SOX6 expression levels across all 22 EwS cell lines (Figure 17A). Subsequently, the results 
were filtered for the significance of the median IC50 values (P value ≤ 0.05) and afterwards sorted by 
their Pearson correlation coefficient (see list 8.6). 
Among the top 7 drugs with the highest Pearson correlation coefficient, the small-molecule Elesclomol 
(N-malonyl-bis (N-methyl-N-thiobenzoyl hydrazide) (rPearson = −0.565; P = 0.014) was the only drug 
inhibiting EwS cell line growth at a nanomolar range (IC50 ~ 25 nM) (Figure 17B). Elesclomol is known 
to be a potent oxidative stress inducer leading cells to apoptosis if levels of oxidative stress rise beyond 
a tolerable threshold (Kirshner et al., 2008). In order to verify these observations a validation 
drug-response assay with Elesclomol was carried out in EwS cell lines with high SOX6 levels (TC-32 and 
RDES) as well as in an osteosarcoma cell line (SAOS-2) and a non-transformed human primary 
mesenchymal stem-cell cell line (MSC-52), both exhibiting low SOX6 expression levels. In agreement 
to the above-stated assumptions, SOX6-low expressing cell lines were more resistant, while EwS cell 
lines were more sensitive toward Elesclomol treatment (Figure 17C, D).  
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As previously reported, SOX6 knockdown contributes to proliferation and cell cycle progression in EwS 
cell lines. This might raise the question whether the reduced sensitivity toward Elesclomol in SOX6-low 
expressing cell lines might result from the reduced proliferation rate upon SOX6 knockdown. The 
analysis of the proliferation rate via Resazurin assay of the involved cell lines revealed that the higher 
sensitivity of EwS cells toward Elesclomol appeared to be independent of proliferation since the 
osteosarcoma cell line SAOS-2 proliferated even more than the tested EwS cells in Resazurin assays 
(Figure 17E). 
Interestingly, the imitation of a SOX6-low expressing EwS cell line was mediated through the 
knockdown of SOX6 in the Dox-inducible RDES and TC-32 EwS cell lines. This experiment revealed that 
SOX6 withdrawal diminished the sensitivity toward Elesclomol pointing to a functional role of SOX6 in 
Elesclomol sensitivity (Figure 17F). 
 
 
Figure 17: SOX6 confers to Elesclomol sensitivity. 
A) Analysis of publicly available matched gene expression and drug-response data (Iorio et al., 2016) 
of up to 22 EwS cell lines per drug. Dark grey: top 7 drugs with P < 0.02; pink: Elesclomol. B) Median 
IC50 values (µM) of the top 7 drugs with P < 0.02. Means and SEM, n ≥ 18 EwS cell lines. C) Resazurin 
assays of different cell lines after treatment with Elesclomol at indicated concentrations for 72h. Black 
and grey: SOX6-high (RDES and TC-32), dark and light red: SOX6-low (SAOS-2, MSC-52), n ≥ 3. D) 
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Analysis of relative SOX6 expression in TC-32, RDES, SAOS-2 and MSC-52 cell lines by qRT-PCR. Means 
and SEM, n ≥ 3. E) Quantification of relative proliferation rate by a Resazurin assay. Means and SEM, 
n ≥ 5. F) Resazurin assay in TC-32 and RDES cell lines with Elesclomol. Pre-treatment with Dox for 48h 
and subsequent addition of Dox and Elesclomol for 72h. Means and SEM, n = 7. ***P < 0.001, **P < 
0.01, *P < 0.05. 
 
In sum, these results demonstrate that SOX6 confers a proliferation-independent sensitivity toward 
Elesclomol in EwS cell lines. 
 
 
4.4.2 Elesclomol induces apoptosis in vitro and necrosis in vivo 
Prior reports showed that Elesclomol inhibits cancer cell growth in breast, melanoma and leukemia 
cell lines (Alli and Ford, 2012; Nagai et al., 2012; Qu et al., 2010; Yadav et al., 2013). It is known that 
Elesclomol elevates oxidative stress-levels beyond a certain threshold, thus triggering the cells into 
apoptosis (Kirshner et al., 2008). In fact, Elesclomol treatment in vitro induced apoptosis in EwS cell 
lines when treated with the corresponding IC50 concentrations (Figure 18A), without affecting SOX6 
expression levels (Figure 18B).  
Furthermore, the effect of Elesclomol in vivo in NGS mice was further investigated. Accordingly, TC-32 
EwS xenografts were administrated intravenously with Elesclomol for 9 days with 5 mg/kg Elesclomol 
or with vehicle (DMSO). The analysis of the tumor volume resulted in reduced local tumor growth of 
these xenografts compared to the DMSO-treated control (Figure 18C). The subsequent 
immunohistological analysis of the extracted tumors showed an increased apoptosis rate evidenced 
by positive cells for cleaved caspase 3 (Figure 18D) and necrotic tumor area (Figure 18E) compared to 
the control tumors treated with DMSO. Noticeably, Elesclomol treatment did not affect mice well-
being as they did not show any differences in weight-loss (Figure 18F). Elesclomol administration also 
did not exert histo-morphological changes in the inner organs (data not shown). 
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Figure 18: Elesclomol induces apoptosis in vitro and in vivo. 
A) Quantification of relative Annexin V positivity of TC-32 and RDES cell lines 48h after Elesclomol 
treatment (10 nM). Mean and SEM, n = 10. P values were determined via unpaired two-sided t-test 
with Welch’s correction. B) Quantification of relative SOX6 expression levels in RDES and TC-32 cells at 
different time points after start of Elesclomol treatment (10 nM). Means and SEM, n ≥ 3. C) Tumor 
volumes of TC-32 EwS xenografts in mice treated once per day (day 0 − 4 and day 7 − 9) with Elesclomol 
intravenously (5 mg/kg). Means and SEM, n = 5 mice per condition. D) Left: Quantification of cleaved 
caspase 3 positive cells/ 3 HPF in TC-32 xenografts shown in (C) by IHC staining. Means and SEM, n = 5 
per condition. Right: Representative pictures; scale bar = 100 µm. E) Left: Quantification of necrotic 
area in TC-32 xenografts shown in (C) by H&E staining. Means and SEM, n = 5 per condition. 
Right: Representative pictures; scale bar = 900 µm. F) Mouse weight over the time during intravenous 
Elesclomol administration (5 mg/kg). Means and SEM, n = 5. G) Analysis of SOX6 expression intensities 
(log2) of primary EwS tumors, melanomas and osteosarcomas (Baldauf et al., 2018b). ***P < 0.001, 
**P < 0.01, *P < 0.05. 
 
In summary, these results demonstrate that Elesclomol contributes to tumor growth reduction in mice 
xenografted with EwS cell lines.  
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4.4.3 SOX6 expression is associated with oxidative stress levels in EwS 
It has been previously reported by Kirshner and colleagues that Elesclomol is able to induce oxidative 
stress (Kirshner et al., 2008). This is due to the ability of Elesclomol to bind and transfer serum Cu(II) 
into mitochondria, where it accumulates and subsequently undergoes a redox reaction. During this 
process, copper is reduced from Cu(II) to Cu(I) thereby releasing free radicals by a Fenton reaction 
(Nagai et al., 2012; Yadav et al., 2013). The precise mechanism of how copper-ligated Elesclomol is 
leading to oxidative stress within the human cell still needs to be elucidated but it has been reported 
in yeast S. cerevisiae, that Elesclomol interacts with the electron transfer chain leading to 
mitochondrial apoptosis (Blackman et al., 2012). In this regard, it has been investigated whether 
Elesclomol treatment could modulate oxidative stress levels in EwS cell lines in the cytosol by DCF-DA 
and in mitochondria by MitoSOX Red fluorescence measurement. A further question was to investigate 
why EwS cells are sensitive to Elesclomol. 
With this objective, EwS cell lines RDES and TC-32 were treated with Elesclomol (10 nM) to investigate 
changes in the oxidative stress levels, both in the cytosol and mitochondria, showing a significant 
induction of oxidative stress level in both EwS cell lines compared to control (DMSO) when quantified 
by DCF-DA and MitoSOX Red fluorescence measurement, respectively (Figure 19A, B). In line with this 
finding, a strong increase of the immunoreactivity for 8-hydroxyguanosine (8-OHG), which is a marker 
for the rate of oxidative damage to nucleic  acids (Curtis et al., 2010; Kasai, 1997) were observed in 
xenografts of mice treated with 5 mg/kg Elesclomol compared to the corresponding DMSO treated 
controls (Figure 19C). 
Since the production of Elesclomol has been discontinued, another known oxidative stress-inducing 
agent called Menadione was used to further explore if the elevated oxidative stress is capable of 
inducing apoptosis in EwS cells. Indeed, drug-response assays reduced sensitivity toward Menadione 
upon SOX6 knockdown in RDES and TC-32 EwS cells compared to the control (Figure 19D).  
To further confirm that elevated oxidative stress levels are responsible for killing EwS cells, two 
experiments with two antioxidants namely N-acetylcysteine (Nac) (Ezeriņa et al., 2018; Zafarullah et 
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al., 2003) and Tiron (Krishna et al., 1992) were carried out. Firstly, cytosolic oxidative stress levels were 
measured by DCF-DA fluorescence and revealed a decrease of oxidative stress levels upon treatment 
with the antioxidants Nac and Tiron (Figure 19E). Secondly, drug-response assays of Elesclomol with 
pre-treatment of antioxidants significantly increased IC50 values (Figure 19F).  
 
Figure 19: Elesclomol confers oxidative stress in vitro and in vivo in EwS.  
A) Quantification of relative DCF-DA fluorescence in TC-32 and RDES cells after Elesclomol treatment 
(10 nM) compared to DMSO control. Means and SEM, n = 8. P values were determined via an 
independent one sample t-test. B) Quantification of MitoSOX Red/MitoTracker Green ratio in TC-32 
and RDES cells after Elesclomol treatment (10 nM) compared to DMSO control. Means and SEM, n = 3. 
P values were determined via an independent one sample t-test. C) Left: IRS of 8-OHG staining are 
presented as dot plots. Horizontal bars represent means. P values determined via two-sided Mann 
Whitney test. Right: Representative picture of 8-OHG staining. Scale bar = 10 µm. D) Quantification of 
relative Elesclomol IC50 values by a Resazurin assay in TC-32 and RDES cell lines after 48h of Dox 
treatment and subsequent addition of Menadione treatment and concomitant SOX6 knockdown for 
72h. E) Quantification of relative DCF-DA fluorescence in TC-32 and RDES cells upon Nac (0.01 mM) or 
Tiron (0.1 mM) treatment compared to control. Means and SEM, n ≥ 3. P values determined via 
independent one sample t-test. F) Top: Schematic illustration of the experiment procedure. Bottom: 
Quantification of relative IC50 concentrations in TC-32 and RDES cells by a Resazurin assays after 
pre-treatment with either the antioxidant Nac or Tiron compared to DMSO control. Horizontal bars 
indicate means and whiskers SEM, n ≥ 4. ***P < 0.001, **P < 0.01, *P < 0.05. 
 
These results were in line with the assumption that Elesclomol exert its pro-apoptotic effect in EwS 
cells partly by induction of oxidative stress beyond a tolerable threshold. 
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In order to evaluate if SOX6 expression is linked to oxidative stress levels, RDES and TC-32 EwS cell lines 
were treated with Dox to ensure SOX6 knockdown and subsequently oxidative stress level changes 
were measured by flow cytometric analysis. The resulting DCF-DA and MitoSOX Red fluorescence was 
reduced upon SOX6 knockdown in both EwS cell lines compared to the corresponding control (Figure 
20A, B). To test whether oxidative stress-dependent sensitivity toward Elesclomol is conferred by SOX6 
expression, rescue experiments with a potent oxidative stress-inducer such as H2O2 were performed. 
Therefore, H2O2 was added to SOX6-silenced EwS cells in a drug-response assay with Elesclomol to 
rescue the SOX6-mediated resistance toward Elesclomol. Indeed, SOX6-silenced EwS cells, treated with 
H2O2, could fully restore the sensitivity of these cell lines toward Elesclomol compared to SOX6-
silenced cells alone (Figure 20C). The H2O2 treatment itself did not have any effect on the cell viability 
of EwS cells (Figure 20D).  
 
 
Figure 20: Elesclomol induces SOX6-mediated oxidative stress-levels in EwS cells. 
A) Quantification of relative DCF-DA fluorescence in TC-32 and RDES cells after Dox-induced SOX6 
knockdown. Means and SEM, n = 5. P values were determined via a one-sample t-test. B) Quantification 
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of MitoSOX Red/MitoTracker Green ratio in TC-32 and RDES cells after dox-induced SOX6 knockdown 
compared to the shCtrl. Menas and SEM, n = 3. P values were determined via an independent one 
sample t-test. C)  Top: Schematic illustration of the experimental procedure. Bottom: Resazurin assays 
of TC-32 and RDES cell lines after Dox-induced SOX6 knockdown with Elesclomol and with H2O2 (30 
mM) treatment for 72h. Means and SEM, n ≥ 5. D) Top: Schematic illustration of experimental 
procedure. Bottom: Analysis of cell viability of indicated cell lines treated with either vehicle (H2O) or 
H2O2 (30 mM) by a Resazurin assay. Means and SEM, n ≥ 5.  ***P < 0.001, **P < 0.01, *P < 0.05. 
 
The above-stated results suggest that SOX6 modulates oxidative stress-dependent sensitivity toward 
Elesclomol. 
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4.4.4 SOX6 regulates Elesclomol sensitivity via TXNIP 
So far, data obtained from previous experiments suggest that SOX6 is involved in oxidative stress 
metabolism. This led to further analysis of the generated microarray data obtained from EwS cells 
with/without SOX6 knockdown (see list 8.4). The microarray data did not show any evidence for a 
systematic enrichment or depletion of oxidative stress-associated pathways in the GSEA (see list 8.5). 
Among the DEGs after SOX6-silencing, thioredoxin interacting protein (TXNIP) was identified (see list 
8.4) as the second most downregulated gene. TXNIP is involved in the thioredoxin antioxidant system, 
where it inhibits the antioxidative function of the redox-protein thioredoxin resulting in an 
accumulation of oxidative stress within the cell (Collet and Messens, 2010).  
To validate the results of the microarray data, SOX6 was silenced in EwS cells for 96h in multiple 
independent experiments. It could be shown that TXNIP levels were indeed reduced at mRNA and 
protein level after this duration (Figure 21A).  
To corroborate the potential link between SOX6 and TXNIP another microarray data set that was 
generated on the same microarray platform, with 18 EwS cell lines with/without EWSR1-FLI1 
knockdown was analyzed (in-house generated data, not published). This dataset revealed a significant 
positive correlation (rPearson = 0.559, P = 0.016) of SOX6 and TXNIP mRNA expression (Figure 21B). 
Furthermore, TXNIP was downregulated in xenografted tumors with/without SOX6 knockdown at 
protein level in vivo (Figure 21C), an observation that strengthens the possible link between SOX6 and 
TXNIP. 
Results 
 
81 
 
 
Figure 21: SOX6 mediates TXNIP expression. 
A) Top: Representative Western blots of TXNIP expression 96h after induction of SOX6 knockdown in 
TC-32 and RDES cells. GAPDH was used as loading control. Bottom: Quantification of relative TXNIP 
mRNA expression by qRT-PCR. Means and SEM, n = 3. B) Correlation of TXNIP and SOX6 mRNA 
expression from 18 EwS cells performed on an Affymetrix Clariom D array. Lines indicate linear 
regression. C) Quantification of the IRS for TXNIP in EwS xenografts with/without SOX6 knockdown in 
TC-32 and RDES cell lines. Data are represented as median IRS, n ≥ 4. P values were determined by 
two-sided unpaired student’s t-test. Representative micrographs are depicted, scale bar = 20 µm. 
***P < 0.001, **P < 0.01, *P < 0.05. 
 
As TXNIP is involved in the antioxidant system, its possible function as oxidative stress-regulator was 
further explored. In order to evaluate if TXNIP is indeed modulating oxidative stress levels in EwS cell 
lines, flow cytometric analysis with DCF-DA and MitoSOX Red fluorescence labeling in TC-32 cell lines 
were performed. Indeed, the knockdown of TXNIP in TC-32 cells (Figure 22A) reduced cytoplasmic 
(Figure 22B) and mitochondrial oxidative stress levels (Figure 22C).  
 
To further validate if TXNIP plays an important role in oxidative stress-mediated sensitivity toward 
Elesclomol, EwS cells were transiently transfected with a siRNA against TXNIP and a drug-response 
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assay was carried out. The knockdown of TXNIP reduced the sensitivity of EwS cells toward Elesclomol 
(Figure 22D). 
For rescue experiments, Dox-inducible SOX6 knockdown EwS cell lines were additionally transduced 
with a cumate-inducible overexpression system that contains a full-length cDNA of TXNIP. Dox addition 
induced 80% knockdown of SOX6 in TC-32 EwS cells and a subsequent reduction of TXNIP onto 10%. 
The cumate-inducible re-expression of TXNIP in SOX6-silenced cells could restore the physiological 
concentration of TXNIP at the mRNA level (Figure 22E). Drug-response assays with Elesclomol revealed 
that the inducible re-expression of TXNIP in SOX6-silenced EwS cells was sufficient to restore ~ 66% of 
the sensitivity toward Elesclomol (Figure 22F). 
 
 
Figure 22: SOX6-mediated TXNIP expression links oxidative stress to Elesclomol sensitivity. 
A) Analysis of relative TXNIP mRNA expression by qRT-PCR in TC-32 cells 96h after siRNA-mediated 
TXNIP knockdown. Means and SEM, n = 5. P value was determined via unpaired two-sided t-test with 
Welch’s correction. B) + C) Analysis of oxidative stress levels by flow cytometric measurement of 
DCF-DA fluorescence or MitoSOX Red/MitoTracker Green ratio in TC-32 cells after siRNA-mediated 
TXNIP knockdown. Means and SEM, n ≥ 4. P value was determined via independent one sample t-test. 
D) Quantification of relative Elesclomol IC50 after siRNA-mediated TXNIP knockdown in TC-32 EwS 
cells. Mean and SEM, n = 4. E) Relative mRNA expression of SOX6 and TXNIP after 96h of Dox and/or 
Cumate treatment in TC-32 EwS cells. Means and s SEM, n ≥ 3. F) Quantification of relative Elesclomol 
IC50 values measured by a Resazurin assay in TC-32 cells harboring a shRNA against SOX6 and/or re-
expression of TXNIP after 72h of Elesclomol treatment. Mean and SEM, n ≥ 5. ***P < 0.001, **P < 0.01, 
*P < 0.05. 
 
In summary, this data implies a possible link between SOX6, oxidative stress and Elesclomol. This 
corroborates the assumption that SOX6 might increase oxidative stress levels through upregulation of 
TXNIP and thus promotes sensitivity toward Elesclomol in EwS cells.  
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In conclusion, the presented data in this thesis offer an insight into the regulation of the transcription 
factor SOX6 via the fusion protein EWSR1-FLI1 binding to an intronic GGAA-mSat of the SOX6 gene. On 
the one hand SOX6 confers proliferation and tumor growth by upregulating cell cycle-related genes. 
On the other side SOX6 interfers with TXNIP, that in turn increases intracellular oxidative stress levels 
and thus promotes Elesclomol sensitivity in EwS cells (Figure 23). 
 
 
Figure 23: Schematic illustration of the EWSR1-FLI1-mediated SOX6 expression and its function in 
EwS. 
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5. Discussion 
EwS is a highly aggressive cancer of bone or soft-tissues that might arise from osteo-chondrogenic 
progenitors. As the developmental transcription factor SOX6 is crucial for endochondral ossification 
and thus for bone development (Hagiwara, 2011; Smits et al., 2001), the aim of this thesis was to 
analyze the role of SOX6 in bone-associated EwS. 
This thesis showed that SOX6 is regulated by the fusion oncogene EWSR1-FLI1 in EwS, resulting in high 
but heterogeneous expression at the mRNA and protein level compared to most normal tissues and 
other cancers. Further analyses revealed that the high SOX6 expression in EwS tumors did not result 
from CNV or differences in promoter methylation.  
Through analysis of publicly available ChIP-seq data, an intronic SOX6-associated GGAA-mSat was 
found to be bound by EWSR1-FLI1. Interestingly, this mSat revealed strong length- and EWSR1-FLI1-
dependent enhancer activity in EwS cell lines. This was supported by the fact, that the maternal and 
paternal alleles from the SOX6-associated mSat revealed that the allele with the higher consecutive 
GGAA-repeats exerted the higher enhancer activity. This result gives rise to the assumption that the 
observed inter-tumor heterogeneity of SOX6 expression in EwS is probably due to different repeat 
numbers of consecutive GGAA-repeats at the SOX6-associated GGAA-mSat locus. These findings are in 
accordance with previously published data, stating that target genes of the fusion oncogene such as 
EGR2 and NR0B1 also showed variable expression most likely caused by differences in the consecutive 
GGAA-repeats at the corresponding GGAA-mSat (Grünewald et al., 2018; Monument et al., 2014). 
The SOX6 gene can act as a splicing factor (Ohe et al., 2002, 2009) or as a transcription factor (Hagiwara, 
2011) depending on the cellular requirement. Transcriptome profiling experiments that contained > 
285,000 transcripts and isoforms did not reveal a strong contribution of SOX6 to alternative splicing in 
EwS. Instead, a combination of microarray data with a GSEA analysis identified a large number of 
deregulated genes after SOX6-silencing. Those genes were significantly enriched for gene sets involved 
in proliferation and cell cycle progression. This finding, is in line with the known role of SOX6 in 
proliferation of chondroblasts and oligodendrocytes. Furthermore, the changes in the cellular 
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transcriptome were verified and observed in functional in vitro and in vivo experiments in frame of this 
thesis.  
SOX6-silencing reduced clonogenic and anchorage-independent growth as well as tumorigenicity in 
EwS cells, probably through the observed delayed transition of the cell cycle and the reduced 
expression of the proliferation marker Ki67 in xenografts. Interestingly, these findings suggest that 
SOX6 acts as an oncogene in EwS, while it also has been reported that SOX6 can act as tumor 
suppressor, for instance in esophageal squamous cell carcinoma and hepatocellular carcinoma (Guo et 
al., 2013; Qin et al., 2011). The actual function of SOX6 in tumors might depend on the cellular 
requirements of the tumor entity.  
Even though treatment options for EwS patients have improved over the last years and mortality could 
subsequently be reduced, novel therapeutic options are still urgently required (Grünewald et al., 2018; 
Thiel et al., 2011). In this regard, this thesis aimed at investigating whether the observed 
overexpression of SOX6 in EwS compared to other sarcomas and normal tissues provides 
vulnerabilities that could be exploited therapeutically. Indeed, analysis of published gene expression 
data with drug-response data revealed seven drugs whose potency was highly dependent on SOX6 
expression. Revising all the listed drugs by their Pearson correlation coefficient and the statistical 
significance of the corresponding IC50 value, those with clinically unrealistic high IC50 values were 
excluded, ending up with the small-molecule Elesclomol.  
Elesclomol is known to be an oxidative-stress inducer as it binds and transports copper across biological 
membranes into the mitochondria, there generating oxidative stress by its redox properties (Nagai et 
al., 2012). Previous reports showed that Elesclomol is able to increase oxidative stress even beyond a 
tolerable threshold, triggering cells into apoptosis (Gibellini et al., 2010; Kirshner et al., 2008; Nagai et 
al., 2012). It has already been shown that Elesclomol inhibits cancer cell growth in vitro at micro-molar 
concentrations in melanoma, breast cancer and leukemia cell lines (Alli and Ford, 2012; Nagai et al., 
2012; Qu et al., 2010; Yadav et al., 2013).  
Discussion 
 
86 
 
Actually, in drug-response analyses SOX6-high expressing EwS cell lines showed sensitivity toward the 
small-molecule Elesclomol, whereas SOX6 knockdown led to resistance of these cells. Interestingly, 
SOX6 itself regulated oxidative stress in EwS cell lines, as oxidative stress and mito-ROS was reduced 
in EwS cell lines upon SOX6 knockdown. Hence, it is tempting to speculate that the sensitivity of EwS 
toward Elesclomol is due to the relatively high SOX6 expression and thereby elevated basic oxidative 
stress level in EwS. An increase of oxidative stress and mito-ROS levels upon Elesclomol-treatment was 
mirrored in functional in vitro and in vivo experiments in EwS cells. The apoptotic effect of Elesclomol 
was again dependent on SOX6 expression. In line, Elesclomol-treatment in SOX6-high expressing cell 
lines with two antioxidants diminished the sensitivity toward Elesclomol, as previously observed in 
case of SOX6 knockdown. Consequently, treatment with an oxidative stress-inducer rescued the 
Elesclomol sensitivity in SOX6 knockdown EwS cell lines.  
Additional analysis of the microarray data revealed a decreased TXNIP expression upon SOX6 
knockdown in EwS suggesting a SOX6-mediated upregulation of TXNIP. This observation could at least 
in part explain the elevated intracellular oxidative stress and mito-ROS levels that are linked to the 
sensitivity of SOX6-high expressing EwS cells toward Elesclomol. Interestingly, TXNIP is an inhibitor of 
the thioredoxin (TRX) antioxidant system that plays an essential role in buffering intracellular oxidative 
stress levels (Burke-Gaffney et al., 2005; Hwang et al., 2014).  
 
Worth to mention, in a phase II and III of clinical trials, Elesclomol was administered in combination 
with paclitaxel to patients suffering from malignant melanoma (O’Day et al., 2009, 2013). However, 
the Elesclomol-treatment did not exert the desired effect as the outcomes could only be moderately 
improved in unselected patients (O’Day et al., 2009, 2013). This might have been circumvented if there 
would have been a preselection of patients with higher SOX6 levels or higher intracellular oxidative 
stress levels. Yet, not only the sensitivity toward Elesclomol is higher in EwS cells, but also primary EwS 
present higher SOX6 expression compared to melanoma or other cancers such as osteosarcoma 
(Figure 18G). Furthermore, Elesclomol mainly targets actively respiring mitochondria, a feature that 
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may reduces its effectiveness in predominantly hypoxic tumors (Yadav et al., 2013). Hypoxic tumors 
are under the control of the hypoxia-inducible factor 1 alpha (HIF-1α), a main response gene that in 
turn leads to increase of Lactate dehydrogenase (LDH) levels (Semenza, 2000). This might also be an 
explanation why a subgroup analysis showed a more favorable outcome from Elesclomol treatment in 
patients with normal versus elevated baseline LDH levels in the phase III clinical trial (O’Day et al., 
2013). 
So far, Elesclomol has only been used as enhancer in combination with other chemotherapeutic drugs 
such as Doxorubin and Paclitaxel. Doxorubicin competes with the coenzyme Q10 in the mitochondria. 
Treatment of breast cancer cells with a combination of Elesclomol and Doxorubicin enhanced the 
apoptosis effect (Qu et al., 2010). Paclitaxel, as Vincristin, are known to inhibit microtubule formation 
and both promotes the release of cytochrome c from the mitochondria. Both pathways (Doxorubicin 
and Paclitaxel/Vincristin) lead to a rise in oxidative stress levels. Actually, standard treatment options 
for EwS include the chemotherapeutic agents Doxorubicin and Vincristin. The author of this thesis 
speculates whether Doxorubicin and Vincristin (besides Etoposide and Ifosfamide), could enhance 
their treatment potency when combined with Elesclomol in EwS. As mentioned before, SOX6 is 
heterogeneously expressed in EwS with certain inter- and intra-tumoral differences meaning that even 
patients with lower SOX6 expression could potentially benefit from this new treatment approach.  
The observations and results of this thesis suggest that the oxidative stress-inducing reagent 
Elesclomol could be considered as a new therapeutic option for a subgroup of EwS patients with high 
levels of SOX6. Additionally, the author of this thesis suggests SOX6 as a biomarker for prediction of 
Elesclomol efficacy in EwS. The appliance of SOX6 as biomarker in other cancer types needs to be 
further validated.  
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6. Conclusions and limitations 
6.1 Conclusions 
This PhD thesis investigated the tumorigenic role of SOX6 in EwS. This project revealed that SOX6 
expression is regulated by EWSR1-FLI1 in EwS. Additionally, this project demonstrated that the 
overexpression of the transcription factor SOX6 contributes to proliferation in vitro and in vivo, 
anchorage-independent clonogenic growth as well as tumorigenicity of EwS.  
SOX6 is highly expressed in EwS and other cancer entities. Although its expression does not correlate 
with survival in EwS patients, SOX6 might still serve as a biomarker and drug enhancer for targeted 
therapy. Supporting this, the underlying thesis elucidated the links between SOX6-mediated TXNIP 
expression, oxidative stress and Elesclomol sensitivity in EwS. 
 
6.2 Limitations  
The result of this PhD thesis illuminated a functional role of SOX6 in EwS progression and its capability 
as a biomarker for Elesclomol treatment in EwS patients. Nevertheless, the complex role of the 
developmental transcription factor SOX6 in EwS need to be further investigated. In the following 
section some open question resulting from this thesis were addressed: 
 
How exactly does SOX6 interfere with TXNIP in EwS? 
This thesis demonstrated that SOX6 in EwS somehow interferes with TXNIP repressing Trx and thereby 
increasing intrinsic oxidative stress levels. It is still unclear how exactly SOX6 interacts with TXNIP on 
the molecular level as unpublished ChIP-seq data for SOX6 (not shown in the thesis) in wildtype and 
SOX6-knockdown EwS cells did not hint to a direct regulation of TXNIP by SOX6. Interestingly, SOX6 
does not possess an own trans-activation domain and its activation is dependend the interaction with 
other proteins. This thesis hint to the fact that SOX6 needs to bind a co-factor, which than in turn 
directly interacts with TXNIP. The full mechanism of how SOX6 interacts with TXNIP and contributes to 
oxidative stress levels in EwS cells needs to be further elucidated. 
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Which role holds SOX6 in endochondral ossification during EwS progression? 
This project pointed out that SOX6 is involved in proliferation, anchorage-independent clonogenic 
growth and tumorigenesis of EwS cells. As a member of the SOX-trio, SOX6 is mainly involved in the 
proliferation of chondroblasts during endochondral ossification. So far, the role of SOX6 in the genesis 
of Ewing sarcoma is unknown. This is partly due to the still unknown cellular origin of EwS and due to 
the lack of an appropriate EwS model mimicking the real EwS from the beginning.  
The analysis of the differentiation capacity with/without SOX6 in vitro by measuring for differentiation 
specific markers or stainings for mineralization did not hint at a differentiation capacity of EwS cells.  
Interestingly, subcutaneous injection of SOX6-silenced EwS cells in mice showed that these knockdown 
cells were able to attract mouse-derived osteoblasts into the EwS tumor environment, which then 
differentiated into woven bone (data not shown in this thesis). Hence, further analysis of the tumor 
microenvironment of SOX6-expressing and SOX6-knockdown cells could reveal important insights into 
the mechanisms of SOX6 acting in EwS, such as by secretory proteins. 
 
 
Is SOX6-mediated Elesclomol sensitivity to other tumor entities with increased SOX6 levels 
(melanoma or glioma) improving clinical output for patients beyond EwS? 
This thesis demonstrated that SOX6 is linked to Elesclomol sensitivity in EwS cells. Overexpression 
experiments of SOX6 in SOX6-low expressing osteosarcoma cell lines U2OS and SAOS-2 were 
performed attempting to restore Elesclomol sensitivity (data not shown). Despite all effort, these 
experiments only revealed restricted effects suggesting other factors might be involved in the 
SOX6-mediated Elesclomol sensitivity at least in osteosarcoma. Thus, it remains unclear if the SOX6-
mediated Elesclomol sensitivity is a phenomenon specific for EwS cells or if this given Elesclomol 
sensitivity could also be a predictive biomarker for other tumor entities. Treatment possibilities for 
SOX6-positive melanoma and glioblastoma patients could thus be improved potentially.  
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8. Appendix 
8.1 1-kb sequence from the reference genome containing SOX6-mSat 
1-kb sequence of the microsatellite (mSat) of SOX6, including 500 bp up- and downstream, from the 
human reference genome (Hg19: chr11:16,371,142-16,371,383). 
 
…GAGATGTGTCAGCAGTCAATCCAAGCAAACGGGTCCTTCTTCAGTTTCTGTCCCACTGTTTCAGATGCCCTGTCTTACCTCACTCT
TCCTTTCACACTTTGTTTTGTTCCATTGGTCTAACTTCCTTCTTGGGGTTACTCTTTCACTACTAAATAAACTTAAACTCCTACAATATT
AGATAGTTCTTATCATCTGTAACATCTTCCCTTACAGCTCTAGAAACAGTAAATCTTGCAAGTAAGTGATGCAGTATCACACTTGAGA
ATTTAATTTATAGGTTTCTATAATTTCCAGAGATACAATCATACCCAGGCATTGTCAATTTTTTATTGCAAAAGTTTGTAGGTTTTCTG
GTTGATATGTGCTTAACTCTAATCCTTAAGAATAAAAGTAAACAACAAATACATTGAATAAACACATATGTGTATACATATTATATGT
TCTGAACATTATTAGGTCATAACCATGCTGAAATGAAAAGAAAGGGGGAGGGAGGGAGGGAGAGAGGAAGGAAGGAAGGAAG
GAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGGAGGGAGGGAGGAAGGGAGGGAGAAGGGG
AAGGGAGGGAGAAGGGGAAGGGAAGAAGGAAGGAAGCTAACTTATCTTTATTAATACAGAAATGTAGCCCTCAGTATAGCTAAT
AAATACTCAAGGCTGTACATCATTGACCCATCTTTAACTCAATACAGTTACTACAGCTTCCATGCAGATATTATCTCAAAATATTATG
CTATATCATACTGACTTAAGTCATAAAGCCAAATCTTTCTTTCTCTGAACTCCCTTATGTGCCTCTTCATTATTCAGAACATCCTGGAC
TGCC… 
 
 
8.2 List of GGAA-repeats of the SOX6-associated GGAA-mSat with different SOX6 expressions and 
its corresponding enhancer activity 
The SOX6 expression level of the following EwS cell lines were measured by RT-qPCR. Three SOX6-high 
expressing cell lines (TC-32, RDES and POE) as well as three SOX6-intermediate expressing cell lines 
(ORS, SK-N-MC and EW17) and two SOX6-low expressing cell lines (EW7 and A673) were separated 
into their maternal and paternal GGAA-mSat alleles (Allele A and B). The amout of consecutive GGAA-
repeats within each allele was determined by Sanger sequencing and their corresponding enhancer 
activity was measured in a luciferase assay. 
  GGAA-repeats Enhancer activity 
Cell line 
Average 
SOX6 
expression 
(%) 
Allele 
A 
Allele 
B 
Average 
number of 
GGAA-
repeats 
Allele 
A 
Allele 
B 
Average 
enhancer 
activity 
Rel. to TC-32 
Enhancer 
activity 
TC-32 100 11 13 12 82 175 129 100 
RDES 77 10 11 10.5 73 127 100 78 
POE 62 10 14 12 48 93 70 54 
ORS 32 10 10 10 50 45 48 37 
SK-N-MC 30 8 11 9.5 36 76 56 44 
EW17 26 9 10 9.5 25 50 38 29 
EW7 7 10 11 10.5 76 86 81 63 
A673 7 8 11 9.5 32 41 37 28 
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8.3 List of analyzed splicing events by microarray 
As SOX6 was reported to be a DNA- and RNA-binding transcription factor, a Human Affymetrix Clariom 
D microarray was performed, that also measured splicing events. An independent one sample t-test 
was applied to determine significance and furthermore corrected for Bonferroni. 
Probe set region Gene Symbol 
P value 
Bonferroni corrected 
PSR1600175052.hg.1 EARS2 0.161 
PSR0200222926.hg.1 CCDC138  0.555 
PSR1500157474.hg.1 MORF4L1 1 
PSR0600180336.hg.1 MDGA1  1 
PSR0300170031.hg.1 ABCF3 1 
PSR0300204354.hg.1 SEMA3B  1 
PSR0200225812.hg.1 SMC6  1 
PSR0800178860.hg.1 ENPP2  1 
PSR0200197661.hg.1 EIF2AK3  1 
PSR0200172036.hg.1 GULP1  1 
PSR1000144236.hg.1 GTPBP4 1 
PSR0600148118.hg.1 JARID2  1 
PSR1200167634.hg.1 ACADS  1 
PSR0700194571.hg.1 MLL3  1 
PSR1100200312.hg.1 NDUFS3  1 
PSR0800179609.hg.1 MTSS1  1 
PSR0100163643.hg.1 CLCA1  1 
PSR1500169532.hg.1 MYO5C  1 
PSR0400184559.hg.1 SPOCK3  1 
PSR1200191400.hg.1 NUAK1  1 
 
8.4 List of differentially expressed genes (DEGs) 
Represented are the DEGs of TC-32 and RDES cell lines (including only genes with minimally expression 
of > 7) sorted by the mean log2-fold change (FC). An independent one sample t-test was applied to 
determine significance and further corrected for Bonferroni correction for multiple testing. As 
statistical power for four samples reached no significance for any gene when applying Bonferroni 
correction for multiple testing, FDR estimation was applied for comparision. Genes that have been 
further validated by qRT-PCR are highlighted.  
Gene symbol ENTREZG Mean_log_2_FC P value P value Bonferroni corrected FDR_estimate 
CDCA3 83461 -2.420 0.012 1 0.237 
TXNIP 10628 -2.339 0.084 1 0.315 
RHOB 388 -2.308 0.003 1 0.197 
PKP2 5318 -2.226 0.173 1 0.435 
CRIP1 1396 -2.216 0.010 1 0.235 
ANLN 54443 -2.192 0.098 1 0.332 
KIF20A 10112 -2.185 0.078 1 0.309 
SHMT2 6472 -2.110 0.167 1 0.426 
KIF4A 24137 -2.108 0.080 1 0.311 
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USE1 55850 -2.071 0.146 1 0.397 
ESYT1 23344 -2.041 0.141 1 0.391 
RAC1 5879 -2.040 0.174 1 0.436 
SKP2 6502 -2.037 0.123 1 0.366 
SHISA5 51246 -2.015 0.033 1 0.259 
RPS16 6217 -1.960 0.184 1 0.449 
EPB41 2035 -1.959 0.215 1 0.489 
CDK2 1017 -1.958 0.052 1 0.280 
CENPM 79019 -1.957 0.054 1 0.282 
C11orf24 53838 -1.950 0.058 1 0.287 
ID1 3397 -1.934 0.003 1 0.198 
FOXM1 2305 -1.930 0.076 1 0.306 
DCTPP1 79077 -1.930 0.152 1 0.406 
ARHGEF39 84904 -1.921 0.071 1 0.301 
UCP2 7351 -1.918 0.160 1 0.417 
E2F8 79733 -1.898 0.047 1 0.274 
FKBP1A 2280 -1.896 0.179 1 0.443 
MICB 4277 -1.887 0.021 1 0.246 
CDCA7 83879 -1.886 0.059 1 0.288 
SLC29A2 3177 -1.884 0.099 1 0.334 
SLC1A5 6510 -1.883 0.108 1 0.345 
PSRC1 84722 -1.865 0.038 1 0.265 
BIRC5 332 -1.846 0.039 1 0.266 
UBE2S 27338 -1.843 0.015 1 0.240 
HN1 51155 -1.838 0.259 1 0.540 
PLP2 5355 -1.836 0.158 1 0.414 
CCNA2 890 -1.832 0.124 1 0.366 
MEGF9 1955 -1.831 0.011 1 0.235 
CCNK 8812 -1.829 0.108 1 0.346 
EPHA2 1969 -1.826 0.016 1 0.241 
LRP8 7804 -1.825 0.030 1 0.256 
SRM 6723 -1.821 0.147 1 0.399 
CD99 4267 -1.809 0.230 1 0.507 
CCNB2 9133 -1.805 0.047 1 0.274 
PMAIP1 5366 -1.803 0.065 1 0.294 
DEPDC1 55635 -1.801 0.030 1 0.256 
TMEM97 27346 -1.786 0.032 1 0.257 
AURKB 9212 -1.784 0.147 1 0.399 
TK1 7083 -1.763 0.107 1 0.344 
NR0B1 190 -1.759 0.341 1 0.622 
ZFP36L2 678 -1.747 0.020 1 0.245 
HIST2H3A 333932 -1.744 0.145 1 0.396 
HIST1H4L 8368 -1.734 0.094 1 0.328 
TFDP1 7027 -1.710 0.057 1 0.285 
C14orf119 55017 -1.697 0.121 1 0.362 
FADS1 3992 -1.692 0.171 1 0.432 
DNAJB1 3337 -1.679 0.004 1 0.201 
E2F2 1870 -1.678 0.030 1 0.256 
CDC20 991 -1.677 0.083 1 0.314 
SLC39A14 23516 -1.671 0.025 1 0.250 
HIST1H2BI 8346 -1.650 0.106 1 0.342 
SLC35A4 113829 -1.650 0.156 1 0.411 
ARPC1A 10552 -1.638 0.237 1 0.515 
MKI67 4288 -1.635 0.115 1 0.354 
C1QL1 10882 -1.634 0.049 1 0.277 
DIXDC1 85458 -1.622 0.006 1 0.222 
IAH1 285148 -1.620 0.042 1 0.269 
MYBL2 4605 -1.603 0.112 1 0.350 
GNG4 2786 -1.601 0.050 1 0.278 
HIST1H2BL 8340 -1.597 0.091 1 0.323 
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AHNAK 79026 -1.588 0.073 1 0.303 
CTGF 1490 -1.586 0.052 1 0.280 
GINS2 51659 -1.584 0.095 1 0.329 
FAM96A 84191 -1.583 0.194 1 0.462 
NRM 11270 -1.581 0.009 1 0.231 
MLX 6945 -1.581 0.074 1 0.304 
ABCB10 23456 -1.571 0.030 1 0.256 
ERH 2079 -1.571 0.181 1 0.445 
CHAC1 79094 -1.570 0.122 1 0.363 
NRSN2 80023 -1.564 0.206 1 0.477 
ACOT7 11332 -1.554 0.033 1 0.259 
KIFC1 3833 -1.542 0.063 1 0.293 
ERHP1 100507125 -1.540 0.150 1 0.403 
TLCD1 116238 -1.533 0.115 1 0.354 
SREBF2 6721 -1.527 0.062 1 0.292 
FAM111B 374393 -1.522 0.050 1 0.278 
SMC2 10592 -1.521 0.061 1 0.290 
CCNB1 891 -1.514 0.061 1 0.290 
CHCHD10 400916 -1.511 0.030 1 0.256 
GPN1 11321 -1.507 0.069 1 0.298 
RNU1-122P 106480190 -1.505 0.045 1 0.272 
ARHGDIA 396 -1.504 0.127 1 0.371 
RANGAP1 5905 -1.504 0.102 1 0.337 
CDK5 1020 -1.503 0.160 1 0.417 
SYTL5 94122 -1.501 0.115 1 0.354 
RRM2 6241 -1.497 0.074 1 0.304 
ITPRIPL1 150771 -1.493 0.096 1 0.330 
GNG10 2790 -1.491 0.016 1 0.241 
HIST1H2BJ 8970 -1.486 0.115 1 0.354 
SOX6 55553 -1.486 0.006 1 0.220 
 
8.5 List of Gene Set Enrichment Analysis of DEGs 
GSEA results of DEGs (including only genes with minimally gene expression of > 7) are sorted by NES 
values. 
NAME NES 
NOM 
p-value 
FDR 
q-value 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER -2.652 0 0 
GAVIN_FOXP3_TARGETS_CLUSTER_P6 -2.528 0 0 
KOBAYASHI_EGFR_SIGNALING_24HR_DN -2.501 0 0 
WHITEFORD_PEDIATRIC_CANCER_MARKERS -2.498 0 0 
DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP -2.475 0 0 
BURTON_ADIPOGENESIS_3 -2.461 0 0 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR -2.456 0 0 
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP -2.456 0 0 
CROONQUIST_IL6_DEPRIVATION_DN -2.447 0 0 
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP -2.444 0 0 
TANG_SENESCENCE_TP53_TARGETS_DN -2.438 0 0 
ISHIDA_E2F_TARGETS -2.436 0 0 
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN -2.422 0 0 
CHANG_CYCLING_GENES -2.421 0 0 
LEE_EARLY_T_LYMPHOCYTE_UP -2.409 0 0 
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN -2.407 0 0 
KONG_E2F3_TARGETS -2.397 0 0 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR -2.393 0 0 
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8.6 List of matched gene expression data with drug response data  
Represented are the Pearson correlation coefficients with the corresponding P value calculated by the 
SOX6 expression and their matching IC50 value (Iorio et al., 2016). An independent one sample t-test 
was applied to determine significance. The list is sorted by the median IC50 values. 
Name Description Median IC50  
Pearson corr. 
coefficient 
 P value 
Elesclomol (STA-
4783) 
Oxidative stress inducer 25 nM –0.565 0.014 
Fedratinib JAK2 inhibitor 2 µM –0.569 0.012 
PHA-793887 CDK2, CDK5, CDK7 inhibitor 3 µM –0.633 0.004 
Serdemetan HDM2 ubiquitin ligase antagonist 11 µM –0.600 0.011 
Rucaparib PARP inhibitor 12 µM –0.665 0.003 
Imatinib v-AbI, c-Kit, PDGFR inhibitor 15 µM –0.556 0.017 
Olaparib PARP1/2 inhibitor 32 µM –0.607 0.005 
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